

CITATION REPORT

List of articles citing

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

DOI: 10.1182/blood-2009-07-235358
Blood, 2010, 115, 453-74.

Source: <https://exaly.com/paper-pdf/47761843/citation-report.pdf>

Version: 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2271	Acute myeloid leukemia. 146-170		
2270	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. 2009 , 2009, 704928		12
2269	Molecular genetics in acute myeloid leukemia. 2010 , 22, 646-55		59
2268	Current world literature. 2010 , 22, 664-8		
2267	High cytogenetic or molecular genetic risk acute myeloid leukemia. 2010 , 2010, 474-80		11
2266	Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation. 2010 , 95, 1969-72		12
2265	P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010 , 116, 1413-21	2.2	98
2264	A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. <i>Blood</i> , 2010 , 116, 2096-102	2.2	28
2263	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. <i>Blood</i> , 2010 , 116, 1839-48	2.2	141
2262	How I treat acute myeloid leukemia. <i>Blood</i> , 2010 , 116, 3147-56	2.2	133
2261	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. <i>Blood</i> , 2010 , 116, 2420-8	2.2	62
2260	Recent advances in bone marrow biopsy pathology. 2010 , 3, 129-136		
2259	Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia. 2010 , 179, 507-10		2
2258	Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma. 2010 , 3, 25		10
2257	Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results. 2010 , 85, 687-90		7
2256	Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. 2010 , 85, 877-81		31
2255	Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. 2010 , 5, e12405		21

2254	Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic. 2010 , 57, 578-89			5
2253	Ghómique des leucémies aiguës myéloïdes de l'adulte. 2010 , 16, 9-15			
2252	Prognostic significance of CEBPA gene mutations in patients with acute myeloid leukemia. 2010 , 6, 363-371			
2251	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 2010 , 28, 5257-64			155
2250	Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. 2010 , 28, 3724-9			110
2249	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 2010 , 28, 2348-55			599
2248	Target of rapamycin signaling in leukemia and lymphoma. 2010 , 16, 5374-80			40
2247	Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. 2010 , 28, 2674-81			217
2246	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. <i>Blood</i> , 2010 , 116, 4086-94	2.2		152
2245	Old-fashioned genetic screens give new insights to DNA replication. 2010 , 9, 4610-1			
2244	Toxicity and lifespan extension: complex outcomes of histone overexpression in budding yeast. 2010 , 9, 4611-2			1
2243	Establishment of sister chromatid cohesion: the role of the clamp loaders. 2010 , 9, 4615			2
2242	Nucleolar structure: it's all in a tangle. 2010 , 9, 4609-10			1
2241	RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease. 2010 , 9, 4607			9
2240	New prognostic markers in acute myeloid leukemia: perspective from the clinic. 2010 , 2010, 47-55			82
2239	Treating the elderly patient with acute myelogenous leukemia. 2010 , 2010, 62-9			33
2238	miR-31 in cancer: location matters. 2010 , 9, 4608-9			9
2237	A combination of 1 β ,25-dihydroxyvitamin D ₃ , a plant-derived antioxidant and an inhibitor of the Cot1/Tlp2 oncogene as molecularly targeted weapons in the hematologist's battle against acute myeloid leukemias. 2010 , 9, 4612-3			

2236	Cdc25 phosphatases: differential regulation by ubiquitin-mediated proteolysis. 2010 , 9, 4613-4		8
2235	Allogeneic stem cell transplantation for acute myeloid leukemia. 2010 , 95, 857-9		18
2234	IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications. 2010 , 95, 1623-7		18
2233	Molecular diagnosis of acute myeloid leukemia. 2010 , 10, 993-1012		13
2232	IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. 2010 , 28, 3636-43		615
2231	Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. 2010 , 28, 4642-8		178
2230	Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. 2010 , 304, 2706-15		254
2229	Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors?. 2010 , 23, 207-16		26
2228	Treatment of older patients with acute myeloid leukaemia. 2010 , 376, 1967-8		9
2227	Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial. 2010 , 376, 1968-70		5
2226	The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. <i>Blood</i> , 2010 , 116, 2315-23	2.2	73
2225	DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. 2010 , 6, 1415-31		15
2224	Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. 2010 , 28, 3890-8		167
2223	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010 , 116, 5660-9	2.2	99
2222	Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. 2010 , 51, 1536-42		24
2221	IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. 2010 , 51, 2285-7		7
2220	Omacetaxine mepesuccinate for the treatment of leukemia. 2011 , 12, 2381-92		13
2219	RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. 2011 , 29, 1364-72		245

2218	Impact of genetic features on treatment decisions in AML. 2011 , 2011, 36-42		47
2217	Low dose cytarabine monotherapy for acute myeloid leukaemia. 2011 ,		
2216	Therapeutic advances in acute myeloid leukemia. 2011 , 29, 487-94		581
2215	New treatments and strategies in acute myeloid leukemia. 2011 , 11 Suppl 1, S60-4		0
2214	Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. 2011 , 20, 287-95		31
2213	Amonafide: a potential role in treating acute myeloid leukemia. 2011 , 20, 995-1003		13
2212	Acute Leukemia. 2011 , 235-250		
2211	Clinical implications of novel mutations in epigenetic modifiers in AML. 2011 , 25, 1119-33		37
2210	[From conventional cytogenetics to microarrays. Fifty years of Philadelphia chromosome]. 2011 , 137, 221-9		2
2209	Histamine dihydrochloride: in the management of acute myeloid leukaemia. 2011 , 71, 109-22		25
2208	Acute myeloid leukaemia: optimal management and recent developments. 2011 , 71, 1537-50		16
2207	Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge. 2011 , 11, 10-6		18
2206	Spotlight on histamine dihydrochloride in acute myeloid leukaemia. 2011 , 28, 325-9		7
2205	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. <i>Blood</i> , 2011 , 117, 2469-75	2.2	276
2204	Novel transplant strategies in adults with acute leukemia. 2011 , 25, 1319-39, ix		
2203	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. <i>Blood</i> , 2011 , 117, 2307-18	2.2	139
2202	Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. 2011 , 25, 1135-61, vii		74
2201	AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. 2011 , 146, 697-708		203

2200	Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. 2011 , 17, 1796-803	108
2199	Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation. 2011 , 17, 1450-1459.e1	39
2198	Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia. 2011 , 17, 1723-4	8
2197	Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. 2011 , 29, 2889-96	306
2196	TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. 2011 , 29, 1373-81	266
2195	Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia. 2011 , 9, 190-5	1
2194	Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. 2011 , 2, 658-68	59
2193	Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia. 2011 , 17, 132-144	
2192	Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia. 2011 ,	1
2191	Evidence-Based Guided Interventions in Acute Leukemia. 2011 ,	
2190	Molecular and cytogenetic abnormalities in acute myeloid leukemia: review and case studies. 2011 , 9, 184-9	4
2189	Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades. 2011 , 44, 660-5	5
2188	Acute myeloid leukemia: update in diagnosis and treatment in Brazil. 2011 , 9, 179-83	1
2187	Genomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal or incomplete karyotype. 2011 , 6, e20607	2
2186	Current world literature. 2011 , 18, 124-31	
2185	Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. 2011 , 96, 1391-4	53
2184	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 2011 , 96, 1488-95	19
2183	Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. 2011 , 96, 1783-91	36

2182	The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. 2011 , 96, 1613-8		11
2181	Hematogones: a new prognostic factor for acute myeloblastic leukemia. <i>Blood</i> , 2011 , 117, 1315-8	2.2	26
2180	MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 2857-67	2.2	74
2179	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 1828-33	2.2	95
2178	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. <i>Blood</i> , 2011 , 117, 2137-45	2.2	306
2177	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011 , 117, 4561-8	2.2	81
2176	Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. <i>Blood</i> , 2011 , 118, 1402-12	2.2	242
2175	Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. <i>Blood</i> , 2011 , 117, 3302-10	2.2	73
2174	Malignant hematologic diseases in adolescents and young adults. <i>Blood</i> , 2011 , 117, 5803-15	2.2	79
2173	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 7007-13	2.2	54
2172	How I treat extramedullary acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 3785-93	2.2	306
2171	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 4188-98	2.2	48
2170	Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. <i>Blood</i> , 2011 , 118, 4258-64	2.2	48
2169	A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 3832-41	2.2	107
2168	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. <i>Blood</i> , 2011 , 118, 6920-9	2.2	216
2167	Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. 2011 , 96, 972-9		49
2166	Hypomethylating agents for adult patients with acute myeloid leukaemia. 2011 ,		
2165	Central nervous system involvement at first relapse in patients with acute myeloid leukemia. 2011 , 96, 1375-9		20

2164	Acute leukemia in adults. 2011 , 17, 203-224	1
2163	Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. 2011 , 96, 491-3	24
2162	Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. 2011 , 96, 914-7	27
2161	Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. 2011 , 96, 1310-7	52
2160	TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. 2011 , 96, 1059-63	26
2159	The European LeukemiaNet: achievements and perspectives. 2011 , 96, 156-62	12
2158	Isolated mediastinal myeloid sarcoma successfully treated with chemoradiotherapy followed by unrelated allogeneic stem cell transplantation. 2011 , 50, 3003-7	8
2157	FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. 2011 , 96, 681-6	35
2156	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 2011 , 9 Suppl 5, S1-32; quiz S33	195
2155	Acute myeloid leukaemia in the elderly: a review. 2011 , 152, 524-42	108
2154	Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. 2011 , 153, 421-36	91
2153	Primary refractory acute myeloid leukaemia - in search of better definitions and therapies. 2011 , 155, 413-9	30
2152	Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia. 2011 , 51, 1546-55	8
2151	Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. 2011 , 162, 792-805	83
2150	Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia. 2011 , 119, 76-84	11
2149	Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure. 2011 , 25, 671-80	36
2148	Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. 2011 , 25, 599-605	30
2147	A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogenous leukaemia patients: a GOELAMS study. 2011 , 25, 939-44	84

2146	Gene expression profiling in MDS and AML: potential and future avenues. 2011 , 25, 909-20	55
2145	Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. 2011 , 25, 1415-22	25
2144	Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. 2011 , 35, 1611-5	7
2143	High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. 2011 , 35, 1585-90	29
2142	Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?. 2011 , 38, 196-214	19
2141	Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review. 2011 , 80, 331-46	19
2140	Differential survival of AML subpopulations in NOD/SCID mice. 2011 , 39, 250-263.e4	19
2139	Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. 2011 , 19, 138-52	456
2138	Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. 2011 , 29, 475-86	430
2137	Unfavorable-risk cytogenetics in acute myeloid leukemia. 2011 , 4, 173-84	14
2136	The prognostic and functional role of microRNAs in acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 1121-9	2.2 218
2135	Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy. 2011 , 90, 733-5	1
2134	ACUTE LEUKEMIAS XIII. 2011 , 90, 25-76	
2133	Treatment and prophylaxis of hematologic malignancy in the central nervous system. 2011 , 13, 400-12	7
2132	Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. 2011 , 86, 203-5	86
2131	Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission. 2011 , 86, 209-13	16
2130	In vivo T-cell depletion with pretransplant low-dose antithymocyte globulin is associated with reduced transplant-related mortality and improved clinical outcome in patients receiving allogeneic hematopoietic stem cell transplantation from unrelated and partially matched related donors. 2011 , 86, 214-7	8
2129	Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. 2011 , 86, 206-9	127

2128	Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. 2011 , 86, 217-20	171
2127	Evaluation of the free β -hemoglobin pool in red blood cells: a new test providing a scale of β -thalassemia severity. 2011 , 86, 199-202	10
2126	Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. 2011 , 86, 227-30	17
2125	High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma. 2011 , 86, 224-7	9
2124	Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?. 2011 , 86, 223-4	6
2123	Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. 2011 , 86, 220-3	27
2122	Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. 2011 , 86, 230-4	16
2121	The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study. 2011 , 86, 437-9	11
2120	Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia. 2011 , 86, 785-7	8
2119	Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. 2011 , 86, 790-2	8
2118	Sideroblastic anemia, iron overload, and ALAS2 R452S in African-American males: phenotype and genotype features of five unrelated patients. 2011 , 86, 787-9	2
2117	Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. 2011 , 86, 796-800	34
2116	An evaluation of concurrent G6PD (A-) deficiency and sickle cell trait in Malian populations of children with severe or uncomplicated P. falciparum malaria. 2011 , 86, 795-6	9
2115	Published guidelines versus real-life practice in the diagnosis and treatment of essential thrombocythemia. 2011 , 86, 792-4	2
2114	Clinical and laboratory features of leukemias at the time of diagnosis: an analysis of 1,004 consecutive patients. 2011 , 86, 800-3	
2113	Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. 2011 , 86, 804-6	23
2112	Changing patterns of splenectomy in transfusion-dependent thalassemia patients. 2011 , 86, 808-10	23
2111	Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. 2011 , 86, 806-8	32

2110	Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. 2011 , 117, 974-81	18
2109	FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?. 2011 , 117, 3293-304	42
2108	Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. 2011 , 117, 4238-46	43
2107	Independent prognostic variables in acute myeloid leukaemia. 2011 , 25, 39-51	80
2106	Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. 2011 , 35, 885-8	7
2105	Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. 2011 , 35, 991-7	34
2104	Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse. 2011 , 96, 640-3	11
2103	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 2011 , 77, 1887-95	59
2102	Leukämien und myelodysplastische Syndrome [Altersadaptierte Therapie bei älteren Patienten. 2011 , 40, 353-357	
2101	Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. 2011 , 11, 1369-80	7
2100	Allogeneic stem cell transplantation in first complete remission. 2011 , 18, 395-400	7
2099	Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. 2011 , 18, 381-7	9
2098	Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells. 2011 , 21, 757-70	48
2097	Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. 2011 , 22, 696-704	30
2096	Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. 2011 , 52, 444-57	11
2095	Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia. 2011 , 3, 697-9	6
2094	Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. 2011 , 2011, 104631	48
2093	Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. 2011 , 29, 2709-16	297

2092	Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. 2011 , 29, 682-9	47
2091	Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. 2011 , 16, 351-6	34
2090	Novel approaches to the treatment of acute myeloid leukemia. 2011 , 2011, 43-50	67
2089	[Physiopathological, diagnostic and therapeutic impacts of chromosomal translocations in hematological malignancies]. 2011 , 98, 1403-18	1
2088	Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation. 2011 , 48, 182-97	22
2087	Cytarabine dose of 36 g/m ² compared with 12 g/m ² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. 2011 , 29, 2696-702	76
2086	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. 2011 , 29, 4417-23	230
2085	Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. 2011 , 29, 2758-65	177
2084	Drosophila: a model for studying genetic and molecular aspects of haematopoiesis and associated leukaemias. 2011 , 4, 439-45	55
2083	Gene mutation and AML pathogenesis. <i>Blood</i> , 2011 , 118, 5366-7	2.2 33
2082	Cytarabine dose for acute myeloid leukemia. 2011 , 364, 1027-36	277
2081	The EBMT activity survey 2008: impact of team size, team density and new trends. 2011 , 46, 174-91	44
2080	Genetische und immunzytometrische Diagnostik bei der akuten myeloischen Leukämie und ihre Bedeutung für die Wahl der Therapiestrategie/Genetic and immunphenotypical diagnostics for acute myeloid leukemia and their implication on treatment strategy. 2012 , 36,	
2079	[Fluorescence in situ hybridization in hematology]. 2012 , 69, 986-93	0
2078	Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission. 2012 , 4, 601-17	10
2077	Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. 2012 , 8, e1002781	223
2076	Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. 2012 , 47, 499-507	73
2075	Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. 2012 , 47, 1436-41	9

2074	Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. 2012 , 18, 6723-31	87
2073	Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. 2012 , 53, 1543-51	9
2072	Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. 2012 , 19, 454-61	36
2071	Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. 2012 , 21, 225-33	19
2070	Current treatment of acute myeloid leukemia. 2012 , 24, 711-9	104
2069	New induction and postinduction strategies in acute myeloid leukemia. 2012 , 19, 76-81	11
2068	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. 2012 , 97, 1736-42	50
2067	Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. 2012 , 30, 2140-6	106
2066	NME1 and NME2 as markers for myeloid leukemias. 2012 , 53, 1441-2	4
2065	Vascular access devices in leukemia: a retrospective review amongst patients treated at the Ottawa Hospital with induction chemotherapy for acute leukemia. 2012 , 53, 1090-5	16
2064	Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. 2012 , 53, 2186-91	6
2063	Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. 2012 , 97, 739-42	24
2062	Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. 2012 , 8, 351-7	3
2061	Health related quality of life and impact of infectious comorbidity in outpatient management of patients with acute leukemia. 2012 , 53, 1896-904	11
2060	Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. 2012 , 30, 2441-8	168
2059	Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. 2012 , 26, 893-901	68
2058	Prognostic markers in AML: focus on CBFL. 2012 , 1, S12-3	1
2057	DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. 2012 , 26, 1106-7	169

2056	Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. 2012 , 26, 289-95		28
2055	Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. 2012 , 26, 381-9		285
2054	Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. <i>Blood</i> , 2012 , 119, 2943-8	2.2	38
2053	Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia. 2012 , 127, 63-71		14
2052	Beteiligung des zentralen Nervensystems bei akuten Leukämien und Lymphomen Indikation und Hinweise zur Durchführung der Diagnostik/Central nervous system involvement in acute leukemia and lymphoma: indications for CNS assessment and advice for diagnostic strategy. 2012 , 36,		
2051	Acute myeloid leukemia: focus on novel therapeutic strategies. 2012 , 6, 205-17		23
2050	Myeloid neoplasias: what molecular analyses are telling us. 2012 , 2012, 321246		2
2049	Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias. 2012 , 57		
2048	Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress. 2012 , 2012, 329061		8
2047	Cytogenetics in Hematology. 2012 , 161-181		
2046	A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. 2012 , 97, 393-401		188
2045	Molecular targeted therapy in acute myeloid leukemia. 2012 , 17 Suppl 1, S59-62		24
2044	Genetic and immunophenotypical diagnostics for acute myeloid leukemia and their implication on treatment strategy1). 2012 , -		
2043	Prise en charge thérapeutique des leucémies aiguës myéloïdes. 2012 , 7, 1-17		
2042	Classification et facteurs pronostiques des leucémies aiguës. 2012 , 7, 1-17		2
2041	Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?. 2012 , 10, 1029-36		23
2040	Newly discovered quick, non-invasive screening method of bone marrow malignancies including various leukemias, Hodgkin's lymphoma, non-Hodgkin's lymphoma, & multiple myeloma by abnormality of small rectangular area within bone marrow organ representation areas of the face. 2012 , 37, 13-47		2
2039	Primetime for chemotherapy in acute myeloid leukemia. 2012 , 97, 1775		1

2038	Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. 2012 , 97, 246-50		43
2037	The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. 2012 , 23, 140-53		34
2036	Acute myeloid leukemia. 395-420		1
2035	Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice. 2012 , 17 Suppl 1, S39-42		6
2034	Therapy-related myeloid neoplasms following treatment with radioiodine. 2012 , 97, 206-12		32
2033	Leucmies aiguës de l'adulte. 2012 , 7, 1-9		
2032	Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. 2012 , 97, 1401-4		52
2031	Numb chin syndrome in acute myeloid leukemia. 2012 , 344, 237-40		5
2030	Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. 2012 , 97, 915-8		24
2029	Acute myeloid leukemia in the elderly. 2012 , 1, 57-69		1
2028	Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 1282-9	2.2	100
2027	Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ. <i>Blood</i> , 2012 , 119, 4499-511	2.2	56
2026	Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. <i>Blood</i> , 2012 , 119, 3561-70	2.2	33
2025	A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 3571-7	2.2	174
2024	Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. <i>Blood</i> , 2012 , 119, 551-8	2.2	120
2023	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012 , 119, e67-75	2.2	59
2022	Acute myeloid leukemia in the real world: why population-based registries are needed. <i>Blood</i> , 2012 , 119, 3890-9	2.2	211
2021	Unveiling the complexity of CK+ AML. <i>Blood</i> , 2012 , 119, 1958-9	2.2	

2020	GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 395-403	2.2	120
2019	Blood consult: monosomal karyotype acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 5659-60	2.2	1
2018	High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 2118-26	2.2	59
2017	Small gene, big number, many effects. <i>Blood</i> , 2012 , 120, 240-1	2.2	5
2016	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 4840-5	2.2	169
2015	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. <i>Blood</i> , 2012 , 120, 4317-23	2.2	217
2014	Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. 2012 , 97, 116-22		67
2013	Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. 2012 , 379, 1508-16		646
2012	Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. <i>Blood</i> , 2012 , 120, 3353-9	2.2	24
2011	Advances in stem cell mobilization. 2012 , 26, 267-78		48
2010	The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. 2012 , 198, 11-21		159
2009	Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. 2012 , 151, 344-55		243
2008	Novel agents in acute myeloid leukemia. 2012 , 96, 178-85		14
2007	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. 2012 , 26, 2462-8		133
2006	Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. 2012 , 5, 547-58		28
2005	The Acute Leukemias. 2012 , 1203-1209		1
2004	Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. <i>Blood</i> , 2012 , 120, 4205-14	2.2	122
2003	Renaissance of autologous stem cell transplantation for AML?. 2012 , 13, 121-3		7

2002	Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting. 2012 , 14, 594-601		11
2001	Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor. 2012 , 32, 1070-7		8
2000	Comparative proteome analysis of acute myeloid leukemia with and without maturation. 2012 , 75, 5734-48		21
1999	[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]. 2012 , 106, 11-22		7
1998	Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD. 2012 , 18, 1845-50		25
1997	[Therapeutic of respiratory manifestations at the early phase of acute myeloid leukaemia]. 2012 , 29, 743-55		3
1996	A novel hierarchical prognostic model of AML solely based on molecular mutations. <i>Blood</i> , 2012 , 120, 2963-72	2.2	189
1995	Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. <i>Blood</i> , 2012 , 120, 2521-8	2.2	49
1994	Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. 2012 , 30, 2670-7		788
1993	Recent developments in management of older patients with acute myeloid leukemia. 2012 , 3, 89-96		6
1992	Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. 2012 , 47, 1442-7		19
1991	New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy. 2012 , 18, 5163-71		12
1990	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. <i>Blood</i> , 2012 , 119, 2314-24	2.2	128
1989	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. 2012 , 26, 2353-9		181
1988	The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. 2012 , 18, 190-9		26
1987	Prognostic factors for therapy-related acute myeloid leukaemia (t-AML)--a single centre experience. 2012 , 66, 285-92		5
1986	Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. 2012 , 413, 1542-8		18
1985	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. 2012 , 9, 579-90		303

1984	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012 , 120, 3187-205	2.2	359
1983	Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. 2012 , 30, 4515-23		310
1982	Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study. 2012 , 87, 1052-6		19
1981	Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression. 2012 , 10, 19		30
1980	MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. 2012 , 5, 26		56
1979	Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. 2012 , 89, 478-90		13
1978	Leukaemias into the 21st century: part 1: the acute leukaemias. 2012 , 42, 1179-86		12
1977	Minimal Residual Disease. 2012 , 281-293		
1976	Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. 2012 , 11, 3219-26		23
1975	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. <i>Blood</i> , 2012 , 120, e83-92	2.2	110
1974	Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. 2012 , 26, 1842-9		33
1973	Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study. 2012 , 47, 46-53		26
1972	How to manage high-risk acute myeloid leukemia. 2012 , 26, 861-9		22
1971	Landscape of TET2 mutations in acute myeloid leukemia. 2012 , 26, 934-42		161
1970	The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. 2012 , 26, 1313-20		78
1969	Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. 2012 , 30, 3604-10		107
1968	Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia. 2012 , 13, 2171-87		4
1967	Chromosomal aberrations and fusion genes in myeloid malignancies. 2012 , 5, 381-93		10

1966	Intensity of conditioning for allogeneic haemopoetic cell transplantation. 2012 , 13, 966-8	4
1965	Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. 2012 , 43, 2167-76	16
1964	Comprehensive profile of cytogenetics in 2308 Chinese children and adults with de novo acute myeloid leukemia. 2012 , 49, 107-13	10
1963	Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. 2012 , 12, 274-9	13
1962	High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk. 2012 , 12, 438-43	4
1961	Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission. 2012 , 12, 444-51	7
1960	Copper levels in patients with hematological malignancies. 2012 , 23, 738-41	29
1959	Leucemias agudas. 2012 , 11, 1268-1279	
1958	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. 2012 , 36, 1112-8	6
1957	MPN blast phase: clinical challenge and assessing response. 2012 , 36, 1496-7	8
1956	Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?. 2012 , 5, 395-407	9
1955	Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. 2012 , 53, 1352-9	66
1954	Management of Myelodysplastic Syndromes and Acute Leukaemia. 2012 , 375-385	
1953	Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. 2012 , 12, 1289-97	4
1952	Acute myeloid leukemia with normal cytogenetics. 2012 , 14, 359-68	9
1951	Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia. 2012 , 29, 2077-82	9
1950	A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma). 2012 , 39, e37-46	5
1949	Polymorphisms in XPC provide prognostic information in acute myeloid leukemia. 2012 , 96, 450-60	9

1948	Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. 2012 , 96, 171-7		20
1947	Acute myeloid leukemia in older adults. 2012 , 96, 186-93		45
1946	The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. 2012 , 13, 1257-69		30
1945	Individualisierte Therapie der akuten myeloischen Leukämie. 2012 , 18, 1084-1092		2
1944	Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse. 2012 , 91, 1871-7		7
1943	Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia. 2012 , 91, 1937-43		9
1942	Intensive chemotherapy for elderly patients with acute myelogenous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS). 2012 , 91, 1533-9		9
1941	The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. <i>Blood</i> , 2012 , 119, 4383-6	2.2	34
1940	Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. 2012 , 26, 1266-76		61
1939	Molecular Diagnostics of Acute Myeloblastic Leukemia. 2012 , 387-410		
1938	Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. 2012 , 47, 1274-82		36
1937	Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?. 2012 , 21, 587-603		20
1936	Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. 2012 , 96, 743-7		8
1935	Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. 2012 , 7, e43185		11
1934	Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. 2012 , 7, e51228		29
1933	Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease. 2013 , 60, 74-82		15
1932	History of leukemia: historical perspectives. 1-20		0
1931	Congrès annuel de la société française d'hématologie. 2012 , 18, 150-182		

1930	Prognosis and Survival in Acute Myelogenous Leukemia. 2012,		2
1929	Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification. 2012,		
1928	The detection of KIT mutations in acute myeloid leukemia. 2012, 10, 286-91		1
1927	Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples. 2012, 5, 6		5
1926	The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. <i>Blood</i> , 2012, 119, 5584-90	2.2	84
1925	The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. 2012, 26, 1713-7		16
1924	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. 2012, 26, 1247-54		109
1923	Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes. 2012, 12, 253-64		17
1922	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. <i>Blood</i> , 2012, 119, 2114-21	2.2	411
1921	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 332-41	2.2	209
1920	miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. 2012, 11, 8		57
1919	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2012, 120, 249-58	2.2	58
1918	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. 2012, 30, 3109-18		195
1917	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 5824-31	2.2	193
1916	Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. 2012, 5, 12		187
1915	Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. 2012, 30, 742-50		215
1914	Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. 2012, 53, 2423-9		37
1913	Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations. 2012, 30, 109-14		11

1912	Molecular markers in acute myeloid leukaemia. 2012 , 96, 153-63		27
1911	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. 2012 , 118, 2411-9		23
1910	Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia. 2012 , 82, 123-31		9
1909	TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. 2012 , 30, 1350-7		166
1908	Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. <i>Blood</i> , 2012 , 119, 2122-5	2.2	59
1907	Diagnostic work-up for clinical and prognostic assessment of acute leukaemia. 2012 , 8, 26-35		0
1906	[Risk-adapted therapy in acute myeloid leukemia]. 2012 , 53, 392, 394-9		
1905	Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. 2012 , 29, 1077-81		22
1904	Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. 2012 , 96, 84-93		27
1903	Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. 2012 , 91, 1051-63		22
1902	Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia. 2012 , 138, 1427-32		31
1901	The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory. 2012 , 34, 21-34		6
1900	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention. 2012 , 156, 468-80		35
1899	Micro RNAs as a new therapeutic target towards leukaemia signalling. 2012 , 24, 363-368		16
1898	Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights. 2012 , 39, 37-46		14
1897	Copy number variations in normal karyotype acute myeloid leukaemia and their association with treatment response. 2012 , 111, 317-24		8
1896	Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. 2012 , 88, 52-60		42
1895	BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis. 2012 , 88, 118-27		20

1894	Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia. 2012 , 89, 53-62	26
1893	The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. 2012 , 36, 479-82	37
1892	Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. 2012 , 87, 45-50	9
1891	FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment. 2012 , 87, 42-4	
1890	Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association. 2012 , 87, 62-5	31
1889	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. 2012 , 87, 89-99	118
1888	Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. 2013 , 27, 353-61	40
1887	The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. 2013 , 27, 100-6	51
1886	Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. 2013 , 27, 238-41	36
1885	Tailoring sparse multivariable regression techniques for prognostic single-nucleotide polymorphism signatures. 2013 , 32, 1778-91	9
1884	A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints. 2013 , 6, 18	3
1883	Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. 2013 , 162, 509-16	127
1882	Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. 2013 , 88, 694-702	6
1881	Acute Leukaemia. 2013 , 43-99	
1880	Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. 2013 , 92, 1389-95	24
1879	Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. 2013 , 27, 1803-12	96
1878	Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. 2013 , 12, 46	46
1877	Impact of genetic targets on cancer therapy. Forward. 2013 , 779, v-vi	1

1876	Deregulation of protein phosphatase expression in acute myeloid leukemia. 2013 , 30, 517	18
1875	Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia. 2013 , 125, 50-3	2
1874	Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?. 2013 , 8, 156-62	6
1873	Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission. 2013 , 98, 186-96	5
1872	Impact of pre-transplant marrow blasts on survival of allogeneic stem cell transplantation in adult acute myeloid leukemia. 2013 , 97, 640-9	3
1871	Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. 2013 , 23, 397-406	23
1870	Novel Molecular Acquisitions in Leukemias. 2013 , 453-493	
1869	Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. 2013 , 37, 1606-11	26
1868	Predictive factors for rapid neutrophil and platelet engraftment after allogeneic peripheral blood stem cell transplantation in patients with acute leukemia. 2013 , 92, 1685-93	5
1867	Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. 2013 , 92, 1543-52	15
1866	Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. 2013 , 92, 1397-403	15
1865	Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. 2013 , 48, 901-7	19
1864	Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. 2013 , 37, 190-6	21
1863	Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. 2013 , 31, 1172-81	112
1862	[Acute myeloid leukemia. Genetic diagnostics and molecular therapy]. 2013 , 54, 171-8	
1861	Monosomal karyotype in acute myeloid leukemia defines a distinct subgroup within the adverse cytogenetic risk category. 2013 , 206, 32-6	13
1860	Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. 2013 , 61, 885-91	103
1859	Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. 2013 , 37, 287-92	33

1858	Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. 2013 , 13, 435-40		23
1857	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AML5G). <i>Blood</i> , 2013 , 121, 4769-77	2.2	129
1856	Animal models of leukemia: any closer to the real thing?. 2013 , 32, 63-76		33
1855	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. 2013 , 49, 590-9		8
1854	Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. 2013 , 37, 998-1003		67
1853	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. 2013 , 31, 3883-8		35
1852	Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. 2013 , 54, 2452-7		10
1851	Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. 2013 , 26, 297-300		19
1850	Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. 2013 , 27, E21-9		15
1849	A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. 2013 , 37, 1502-8		16
1848	The biology and clinical impact of genetic lesions in myeloid malignancies. <i>Blood</i> , 2013 , 122, 3741-8	2.2	37
1847	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. 2013 , 6, 78		35
1846	A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13). 2013 , 6, 40		1
1845	Patient Activation through Counseling and Exercise--Acute Leukemia (PACE-AL)--a randomized controlled trial. 2013 , 13, 446		16
1844	Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia. 2013 , 20, 58		20
1843	The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. 2013 , 5, 13		41
1842	Overexpression of primary microRNA 221/222 in acute myeloid leukemia. 2013 , 13, 364		38
1841	Proven invasive pulmonary mucormycosis successfully treated with amphotericin B and surgery in patient with acute myeloblastic leukemia: a case report. 2013 , 7, 263		9

1840	Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation. 2013 , 30, 725		17
1839	A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia. 2013 , 161, 794-801		7
1838	Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. 2013 , 19, 1102-8		15
1837	Impact of allogeneic haematopoietic stem cell transplantation in patients with abn(17p) acute myeloid leukaemia. 2013 , 161, 237-44		21
1836	Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors. 2013 , 155, 43-6		17
1835	The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia. 2013 , 31, 605-21		9
1834	Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene. 2013 , 54, 867-70		11
1833	Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?. 2013 , 14, 1417-27		21
1832	Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyl-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. 2013 , 54, 1996-2002		24
1831	Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemia. 2013 , 6, 131-3		1
1830	Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2013 , 121, 840-8	2.2	21
1829	Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. <i>Blood</i> , 2013 , 122, 1088-9	2.2	77
1828	Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. 2013 , 37, 32-6		26
1827	Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. 2013 , 13, 139-43		4
1826	Genetic profiling in acute myeloid leukaemia--where are we and what is its role in patient management. 2013 , 160, 303-20		44
1825	Impact of genetic targets on cancer therapy in acute myelogenous leukemia. 2013 , 779, 405-37		2
1824	Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , 2013 , 121, 2424-31	2.2	75
1823	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 2213-23	2.2	248

1822	Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. 2013 , 37, 197-200	8
1821	Leukemias. 2013 , 675-690	
1820	Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia. 2013 , 54, 1500-4	3
1819	FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. 2013 , 88, 56-9	62
1818	Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. 2013 , 84, 21-9	37
1817	Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. 2013 , 13, 153-8	10
1816	The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. 2013 , 37, 245-50	31
1815	Are immunoconjugates approaching "standard of care" in AML?. 2013 , 26, 261-8	
1814	Leczenie celowane w ostrych białczkach szpikowych. 2013 , 44, 85-92	
1813	Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden. 2013 , 19, 653-60	24
1812	Transcription factor AP-2 β regulates acute myeloid leukemia cell proliferation by influencing Hoxa gene expression. 2013 , 45, 1647-56	27
1811	Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. 2013 , 46, 554-62	14
1810	The evolving challenge of therapy-related myeloid neoplasms. 2013 , 26, 309-17	56
1809	Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. 2013 , 41, 799-807.e431	
1808	DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. 2013 , 37, 1445-50	58
1807	Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. 2013 , 49, 403-10	19
1806	Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study. 2013 , 37, 862-7	10
1805	CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FLT3-ITD in acute myeloid leukemia with the NPM1-mutation. 2013 , 37, 624-30	16

1804	The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. 2013 , 37, 1052-6		6
1803	Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. 2013 , 37, 1468-71		5
1802	Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China. 2013 , 37, 657-64		13
1801	Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 2013 , 27, 13-22		74
1800	Prognostic risk score for the survival of elderly patients with acute myeloid leukaemia comprising comorbidities. 2013 , 30, 394		10
1799	Notch pathway activation targets AML-initiating cell homeostasis and differentiation. 2013 , 210, 301-19		117
1798	TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. <i>Blood</i> , 2013 , 121, 1304-15	2.2	88
1797	New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. 2013 , 52, 385-401		13
1796	Cytological characterization of murine bone marrow and spleen hematopoietic compartments for improved assessment of toxicity in preclinical gene marking models. 2013 , 92, 595-604		5
1795	CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. 2013 , 48, 1070-6		33
1794	Immunobiology of Acute Leukemia. 2013 , 241-283		
1793	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. 2013 , 27, 780-91		222
1792	Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia. 2013 , 90, 385-96		23
1791	Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. 2013 , 27, 1229-35		163
1790	Refining the diagnosis and prognostic categorization of acute myeloid leukemia patients with an integrated use of cytogenetic and molecular studies. 2013 , 129, 65-71		3
1789	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. 2013 , 27, 1401-3		88
1788	Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription. 2013 , 32, 2069-78		16
1787	Acute myeloid leukemia: 2013 update on risk-stratification and management. 2013 , 88, 318-27		214

1786	Gene mutations of acute myeloid leukemia in the genome era. 2013 , 97, 165-74	48
1785	Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. 2013 , 22, 551-63	24
1784	Acute myeloid leukaemia in adults. 2013 , 381, 484-95	360
1783	Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. 2013 , 27, 836-42	39
1782	Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia. 2013 , 92, 173-7	3
1781	Identification of novel FLT3 kinase inhibitors. 2013 , 63, 713-21	5
1780	Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. 2013 , 6, 9-24	12
1779	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. 2013 , 54, 1228-34	31
1778	Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. 2013 , 368, 2059-74	3137
1777	Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia. 2013 , 999, 105-21	1
1776	Decitabine: a review of its use in older patients with acute myeloid leukaemia. 2013 , 30, 447-58	12
1775	Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. 2013 , 14, 599-608	75
1774	Mitochondrial cytochrome c oxidase subunit II variations predict adverse prognosis in cytogenetically normal acute myeloid leukaemia. 2013 , 91, 295-303	5
1773	Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia: Use of Busulfan/Fludarabine for Conditioning. 2013 , 263-269	
1772	Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. 2013 , 31, 321-7	55
1771	Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. 2013 , 6, 767-84	22
1770	To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. 2013 , 48, 1497-505	62
1769	Infiltrations pulmonaires spécifiques à la phase initiale des leucémies aiguës myéloïdes: le poumon leucémique du diagnostic au traitement. 2013 , 22, 462-469	

1768	Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. 2013 , 31, 3898-905	52
1767	Robustness of amplicon deep sequencing underlines its utility in clinical applications. 2013 , 15, 473-84	44
1766	High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. 2013 , 31, 2094-102	53
1765	Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. 2013 , 3, 1416-29	247
1764	Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. 2013 , 2013, 324-30	39
1763	Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. 2013 , 31, 95-103	74
1762	Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. 2013 , 54, 336-41	10
1761	CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis. 2013 , 18, 61-8	4
1760	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?. 2013 , 2013, 220-6	164
1759	Molecular cytogenetics and multiplex reverse-transcriptase polymerase chain reaction for risk stratification in acute myeloid leukemia. 2013 , 31, 2360-1	2
1758	Novel treatment options for acute myelocytic leukemia. 2013 , 3, 979-990	
1757	Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression. 2013 , 14, 17-23	7
1756	Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. 2013 , 98, 591-6	49
1755	Development of a curative treatment within the AML-BFM studies. 2013 , 225 Suppl 1, S79-86	15
1754	Research Highlights. 2013 , 10, 531-533	
1753	Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?. 2013 , 38, 73-84	12
1752	Akute Myeloische Leukämie - Individualisierte Therapieansätze für eine genetisch heterogene Erkrankung. 2013 , 42, 326-331	
1751	Decitabine for the treatment of acute myeloid leukemia. 2013 , 1, 661-673	3

1750	Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features. 2013 , 35, 581-8	25
1749	Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. 2013 , 31, 4123-31	216
1748	Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia. 2013 , 5, e2013018	3
1747	Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy. 2013 , 5, e2013050	6
1746	The Challenge of AML in Older Patients. 2013 , 5, e2013038	8
1745	Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation. 2013 , 2013, 565824	7
1744	Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells. 2013 , 126, 4746-55	18
1743	Reply to K. Orendi et al. 2013 , 31, 2361-2	0
1742	The evolving molecular genetic landscape in acute myeloid leukaemia. 2013 , 20, 79-85	48
1741	Acute myeloid leukemia in first remission: to choose transplantation or not?. 2013 , 31, 1262-6	23
1740	Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. 2013 , 31, 701-9	75
1739	Defining patient-specific risk in acute myeloid leukemia. 2013 , 31, 3857-9	4
1738	[Major therapeutic advances and new perspectives in onco-hematology]. 2013 , 100, 587-99	8
1737	Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?. 2013 , 2013, 209-19	43
1736	MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. 2013 , 73, 5569-79	43
1735	Central nervous system (CNS) involvement in acute leukemia and lymphoma: indications for CNS assessment and advice for diagnostic strategy1). 2013 , 36,	
1734	MicroRNA dysregulation in acute myeloid leukemia. 2013 , 31, 2065-6	14
1733	Update on optimal management of acute myeloid leukemia. 2013 , 7, 181-97	10

1732	The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias. 2013 , 2013, 275760	6
1731	Daunorubicin, cytarabine, and cladribine regimen plus radiotherapy and donor lymphocyte infusion for extramedullary relapse of acute myeloid leukemia after hematopoietic stem cell transplantation. 2013 , 2013, 258028	2
1730	2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. 2013 , 54, 408-10	19
1729	Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia. 2013 , 88, 1090-3	3
1728	The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies. 2013 , 119, 3326-33	9
1727	ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. 2013 , 27, 82-91	154
1726	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. 2013 , 163, 214-22	28
1725	Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model. 2013 , 5, 1804-20	25
1724	Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. 2013 , 48, 56-62	13
1723	A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. 2013 , 163, 130-2	
1722	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. 2013 , 54, 1028-35	24
1721	A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. 2013 , 27, 2023-31	45
1720	High-risk acute myelogenous leukemia: treatment today ... and tomorrow. 2013 , 2013, 201-8	22
1719	PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17). 2013 , 19, 2562-71	29
1718	Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2013 , 24 Suppl 6, vi138-43	74
1717	Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. 2013 , 31, 4215-21	118
1716	Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. 2013 , 31, 2086-93	141
1715	T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. <i>Blood</i> , 2013 , 122, 3138-48	2.2 260

1714	Idarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemia. 2013 ,		1
1713	Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AML5G). <i>Blood</i> , 2013 , 121, 170-7	2.2	134
1712	The myth of the second remission of acute leukemia in the adult. <i>Blood</i> , 2013 , 121, 1077-82	2.2	163
1711	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 2618-26	2.2	74
1710	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. <i>Blood</i> , 2013 , 121, 4056-62	2.2	206
1709	MRD in AML: time for redefinition of CR?. <i>Blood</i> , 2013 , 121, 2166-8	2.2	21
1708	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. <i>Blood</i> , 2013 , 122, 1455-63	2.2	313
1707	Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). <i>Blood</i> , 2013 , 122, 1087-8	2.2	50
1706	The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. <i>Blood</i> , 2013 , 122, 1576-82	2.2	115
1705	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013 , 122, 1813-21	2.2	264
1704	Protein expression and subcellular localization of familial acute myelogenous leukemia-related factor. 2013 , 30, 2672-6		3
1703	Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. 2013 , 98, 518-25		27
1702	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. 2013 , 98, 1014-21		83
1701	Minimal residual disease testing in acute leukemia. 2013 , 2, 467-485		4
1700	Case Study Interpretation-Fort Lauderdale: Case 3. 2013 ,		
1699	Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia. 2013 , 5, 857-74		12
1698	Prognostic factors and treatment of acute myeloid leukemias in adults (except for APL). 2013 , 19, 69-77		
1697	A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia. 2013 , 98, 913-7		11

1696	HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. 2013 , 98, 1216-25	27
1695	[Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 6. Indication and clinical outcome of hematopoietic stem cell transplantation for acute leukemia]. 2013 , 102, 1728-36	
1694	[Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 1. Treatment for adult acute myeloid leukemia]. 2013 , 102, 1687-95	
1693	Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. 2013 , 12, 5414-23	5
1692	Euphorbia formosana root extract induces apoptosis by caspase-dependent cell death via Fas and mitochondrial pathway in THP-1 human leukemic cells. 2013 , 18, 1949-62	12
1691	Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia. 2013 , 13, 791-810	9
1690	Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients. 2013 , 48, 24-30	10
1689	AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. 2013 , 8, e53518	30
1688	Mechanisms of cyclic nucleotide phosphodiesterases in modulating T cell responses in murine graft-versus-host disease. 2013 , 8, e58110	13
1687	Deregulation of mitochondrial ATPsyn- β in acute myeloid leukemia cells and with increased drug resistance. 2013 , 8, e83610	14
1686	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. 2013 , 18, 1311-34	46
1685	MLL Gene Alterations in Acute Myeloid Leukaemia (11q23/MLL+ AML). 2013 ,	
1684	Is CCDC26 a Novel Cancer-Associated Long-Chain Non-Coding RNA?. 2013 ,	
1683	Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines. 2013 , 35, 56-61	5
1682	Normal-Karyotype Acute Myeloid Leukemia. 2014 , 1644-1663	0
1681	Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. 2014 , 9, e92470	26
1680	Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia. 2014 , 9, e84150	24
1679	Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. 2014 , 9, e93353	34

1678	Acute myelogenous leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: retrospective analysis of molecular genetic evaluation. 2014 , 27, 299-304	1
1677	Clinical study on prospective efficacy of all-trans Acid, realgar-indigo naturalis formula combined with chemotherapy as maintenance treatment of acute promyelocytic leukemia. 2014 , 2014, 987560	5
1676	Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation. 2014 , 2014, 404096	10
1675	Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. 2014 , 3, 1466-89	7
1674	Profile of pacritinib and its potential in the treatment of hematologic disorders. 2014 , 5, 143-52	16
1673	Isolated extramedullary breast relapses in inv(16) positive and c-KIT negative acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation - description of two cases. 2014 , 10, 632-5	
1672	Four cases of chronic myelogenous leukemia in mixed phenotype blast phase at initial presentation mimicking mixed phenotype acute leukemia with t(9;22). 2014 , 34, 60-3	7
1671	Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia - preliminary report. 2014 , 18, 241-5	1
1670	Do ABC proteins still have a role to play in acute myeloid leukemia?. 2014 , 20, 264-275	
1669	Intermediate-risk acute myeloid leukemia therapy: current and future. 2014 , 2014, 34-43	2
1668	Devenir des patients en premièe rechute de leuchmies aiguës myéloïdes ^ core binding factor : une tude r̄trospective fran̄aise. 2014 , 20, 245-246	
1667	Targeted alpha-particle immunotherapy for acute myeloid leukemia. 2014 , e126-31	48
1666	New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencing. 2014 , e334-40	9
1665	Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era. 2014 , e327-33	7
1664	Induction Therapy in Acute Myeloid Leukemia. 2014 , 58-66	1
1663	Prognosis in Acute Myeloid Leukemia: Cytogenetics and Beyond. 2014 , 49-57	
1662	Conditioning regimens in acute myeloid leukemia. 2014 , 7, 465-79	1
1661	Minimalna choroba resztkowa w ostrych białczkach u dzieci i dorosłych. 2014 , 45, 330-339	

1660	Long-term follow-up of cytogenetically normal CEBPA-mutated AML. 2014 , 7, 55		30
1659	Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. 2014 , 7, 74		60
1658	Epigenetic Modifications Mediated by the AML1/ETO and MLL Leukemia Fusion Proteins. 2014 , 121-144		
1657	Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. 2014 , 28, 967-70		12
1656	Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. 2014 , 4, e188		39
1655	MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. 2014 , 28, 804-12		51
1654	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. 2014 , 28, 779-86		81
1653	Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype. 2014 , 167, 671-80		10
1652	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. <i>Blood</i> , 2014 , 124, 1312-9	2.2	49
1651	Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome. 2014 , 28, 723-5		2
1650	Impact of chemotherapy delay on short- and long-term survival in younger and older AML patients: a Danish population-based cohort study. 2014 , 28, 1926-9		12
1649	Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). 2014 , 49, 756-60		27
1648	Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. 2014 , 99, 46-53		35
1647	The state of the union on treatment of acute myeloid leukemia. 2014 , 55, 2423-5		6
1646	Daunorubicin for the treatment of acute myeloid leukemia. 2014 , 2, 1075-1087		
1645	Isolated gastric myeloid sarcoma: a case report and review of the literature. 2014 , 2014, 541807		9
1644	Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation. 2014 , 2014, 123079		14
1643	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. 2014 , 2014, 21-33		29

1642	Intermediate-risk acute myeloid leukemia therapy: current and future. 2014 , 2014, 34-43	22
1641	Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? 2014 , 2014, 222-33	42
1640	Post-remission therapy of adult acute myeloid leukemia: High dose cytosine-arabinoside versus other consolidation regimens. 2014 , 67, 83-90	3
1639	Network-based sub-network signatures unveil the potential for acute myeloid leukemia therapy. 2014 , 10, 3290-7	4
1638	Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. 2014 , 20, 2226-35	56
1637	Tailored central nervous system-directed treatment strategy for isolated CNS recurrence of adult acute myeloid leukemia. 2014 , 19, 208-12	7
1636	Patient-specific microRNA expression profiles as a marker for minimal residual disease in acute myeloid leukemia. 2014 , 19, 18-21	3
1635	Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. 2014 , 99, 836-47	123
1634	Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison. 2014 , 60, 368-74	9
1633	Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. 2014 , 99, 1317-25	61
1632	Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. 2014 , 55, 1925-9	49
1631	Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. 2014 , 55, 1510-7	12
1630	Raman spectroscopy for the assessment of acute myeloid leukemia: a proof of concept study. 2014 ,	0
1629	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. 2014 , 99, 308-13	28
1628	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. 2014 , 111, 18679-84	181
1627	Alternative donor transplantation for adults with acute leukemia. 2014 , 27, 272-7	17
1626	DNMT3A: the DioNysian MonsTer of acute myeloid leukaemia. 2014 , 5, 187-96	8
1625	De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with 80% blasts in older adults: a Bone Marrow Pathology Group study. 2014 , 89, E193-9	17

1624	Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. 2014 , 49, 895-901	34
1623	Detection of clonal evolution in hematopoietic malignancies by combining comparative genomic hybridization and single nucleotide polymorphism arrays. 2014 , 60, 1558-68	8
1622	Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 2014 , 120, 855-63	23
1621	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. 2014 , 99, 1762-8	24
1620	Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations. 2014 , 93, 533-6	11
1619	Rapid remineralization of multiple disseminated bone lesions after high-dose cytarabine in a patient with isolated myeloid sarcoma. 2014 , 92, 537-40	2
1618	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. 2014 , 38, 1435-40	39
1617	Transplantation in acute myeloid leukemia. 2014 , 28, 983-94	6
1616	Acute myeloid leukemia: 2014 update on risk-stratification and management. 2014 , 89, 1063-81	104
1615	Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. 2014 , 120, 1010-7	21
1614	Diagnostic moléculaire des hémopathies malignes. 2014 , 57-80	
1613	[Current indications of allogeneic stem cell transplant in adults with acute myeloid leukemia]. 2014 , 101, 856-65	1
1612	Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. 2014 , 2, 18	22
1611	Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. 2014 , 49, 1129-38	45
1610	Acute Myeloid Leukemia. 2014 ,	
1609	Distress in patients with acute leukemia: a concept analysis. 2014 , 37, 218-26	12
1608	Advances in the treatment of elderly and frail patients with acute myeloid leukemia. 2014 , 26, 663-9	4
1607	Genetic mutations in acute myeloid leukemia that influence clinical decisions. 2014 , 21, 87-94	8

1606	Secondary diffuse large B-cell lymphoma after chemotherapy for acute myeloid leukemia: looking for the unexpected diagnosis. 2014 , 36, e125-8		3
1605	New strategies for relapsed acute myeloid leukemia: fertile ground for translational research. 2014 , 21, 79-86		14
1604	A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic VβVβ T cells. 2014 , 37, 321-30		16
1603	Post-remission therapy for acute myeloid leukemia. 2014 , 99, 1663-70		69
1602	Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells. 2014 , 45, 2076-84		21
1601	Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? <i>Blood</i> , 2014 , 124, 3345-55	2.2	185
1600	Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. <i>Blood</i> , 2014 , 124, 1304-11	2.2	60
1599	Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. 2014 , 18, 1237-51		17
1598	The epigenetic landscape of acute myeloid leukemia. 2014 , 2014, 103175		61
1597	In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells. 2014 , 2014, 143479		8
1596	Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis. 2014 , 2, 275-281		36
1595	The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia. 2014 , 131, 148-52		3
1594	Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital. 2014 , 132, 144-51		9
1593	Genomic characterization of acute leukemias. 2014 , 23, 487-506		20
1592	Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program. 2014 , 55, 2549-55		11
1591	Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia. 2014 , 80, 424-31		13
1590	Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. 2014 , 28, 129-37		79
1589	Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces. 2014 , 35, 1411-9		19

1588	Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. 2014 , 14, 80-6	34
1587	Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients. 2014 , 38, 850-6	15
1586	Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. 2014 , 55, 855-62	13
1585	Acute myeloid leukemia in the elderly: do we know who should be treated and how?. 2014 , 55, 979-87	29
1584	Significance of GRP78 expression in acute myeloid leukemias. 2014 , 9, 204-209	1
1583	Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. 2014 , 93, 193-202	7
1582	Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery. 2014 , 7, 5	43
1581	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. 2014 , 89, 610-5	19
1580	Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission. 2014 , 99, 296-304	7
1579	Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics. 2014 , 14, 69	31
1578	Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. 2014 , 32, 288-96	73
1577	Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. 2014 , 165, 17-38	62
1576	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. 2014 , 38, 551-6	8
1575	Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. 2014 , 89, 410-6	78
1574	Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. 2014 , 20, 2400-9	74
1573	MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. 2014 , 25, 652-65	206
1572	Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). 2014 , 93, 47-55	47
1571	Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. 2014 , 32, 1586-94	68

1570	Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia. 2014 , 446, 280-5		11
1569	Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 2014 , 38, 649-59		35
1568	Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. 2014 , 28, 50-8		68
1567	Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. 2014 , 61, 68-73		9
1566	Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. 2014 , 28, 321-8		26
1565	Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. 2014 , 55, 1533-7		37
1564	Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. 2014 , 55, 1725-34		18
1563	Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis. 2014 , 93, 279-85		15
1562	Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. 2014 , 28, 1001-7		26
1561	Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. 2014 , 28, 713-6		25
1560	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. <i>Blood</i> , 2014 , 123, 914-20	2.2	129
1559	Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. <i>Blood</i> , 2014 , 123, 894-904	2.2	82
1558	Persistence of DNMT3A mutations at long-term remission in adult patients with AML. 2014 , 167, 478-86		99
1557	Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients. 2014 , 10, 246-54		4
1556	Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China. 2014 , 20, 1932-9		18
1555	Outcome of acute myeloid leukemia and high-risk myelodysplastic syndrome according to health insurance status. 2014 , 14, 509-13		2
1554	Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement. 2014 , 20, 2029-33		21
1553	IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. 2014 , 92, 471-7		31

1552	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. 2014 , 28, 1754-1758	20
1551	Mutation profiling and prediction of outcome in acute myeloid leukemia. 2014 , 3, 87-90	
1550	miR-9 is a tumor suppressor in pediatric AML with t(8;21). 2014 , 28, 1022-32	62
1549	Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia. 2014 , 28, 1935-7	9
1548	Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen. 2014 , 14, 493-500	5
1547	A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. 2014 , 167, 185-93	100
1546	Aberrant proteomic expression of NSRP70 and its clinical implications and connection to the transcriptional level in adult acute leukemia. 2014 , 38, 1252-9	2
1545	Evolving treatment strategies in patients with high-risk acute myeloid leukemia. 2014 , 55, 2438-48	8
1544	Translational implications of somatic genomics in acute myeloid leukaemia. 2014 , 15, e382-94	87
1543	Acute leukemia. 2014 , 32, 579-96	19
1542	Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. 2014 , 14, 1971-6	28
1541	Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia. 2014 , 20, 1586-91	22
1540	Les biomarqueurs moléculaires en oncologie. 2014 ,	
1539	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. 2014 , 28, 1586-95	161
1538	Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia. 2014 , 16, 481-8	23
1537	Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. 2014 , 89, 487-92	8
1536	Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. 2014 , 89, 399-403	20
1535	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. 2014 , 20, 490-8	82

1534	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. 2014 , 28, 1252-1258	38
1533	Integrating genomics into prognostic models for AML. 2014 , 51, 298-305	6
1532	AML genomics for the clinician. 2014 , 51, 322-9	4
1531	Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. 2014 , 10, 1157-65	20
1530	FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia. 2014 , 93, 577-93	14
1529	Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. 2014 , 93, 1279-86	65
1528	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. 2014 , 93, 1695-703	21
1527	Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). 2014 , 140, 1391-7	5
1526	Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. 2014 , 6, 34	25
1525	A novel self-lipid antigen targets human T cells against CD1c(+) leukemias. 2014 , 211, 1363-77	69
1524	Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. 2014 , 4, e218	183
1523	Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?. 2014 , 18, 929-44	6
1522	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. <i>Blood</i> , 2014 , 124, 13-23	2.2 115
1521	Recent discoveries in molecular characterization of acute myeloid leukemia. 2014 , 9, 93-9	14
1520	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?. 2014 , 9, 128-37	2
1519	Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages. 2014 , 70, 273-7	35
1518	Expression of Eph A4, Eph B2 and Eph B4 receptors in AML. 2014 , 20, 901-7	8
1517	Investigation of a novel biomarker, neuropilin-1, and its application for poor prognosis in acute myeloid leukemia patients. 2014 , 35, 6919-24	7

1516	Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. 2014 , 13, 116	22
1515	A phase I study of the first-in-class antimetabolic agent, CPI-613, in patients with advanced hematologic malignancies. 2014 , 20, 5255-64	60
1514	Response evaluation and monitoring of multiple myeloma. 2014 , 7, 33-42	7
1513	Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age. 2014 , 167, 162-76	11
1512	Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. 2014 , 89, 423-8	36
1511	Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia. 2014 , 3, 17-20	1
1510	Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?. 2014 , 20, 80-8	7
1509	Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. 2014 , 38, 469-74	27
1508	New avenues for genetics guided therapeutic approaches in AML. 2014 , 45, 322-329	1
1507	Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. 2014 , 38, 564-8	10
1506	Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. 2014 , 14, 305-18	24
1505	High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission?. 2014 , 31, 980	4
1504	European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. 2014 , 4, e216	5
1503	Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. 2014 , 55, 2691-8	34
1502	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. 2014 , 28, 1774-83	184
1501	Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin. 2014 , 20, 1399-406	8
1500	Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution. 2014 , 38, 907-12	3
1499	Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome. 2014 , 53, 144-8	10

1498	Current knowledge and future research directions in treatment-related second primary malignancies. 2014 , 12, 5-17		39
1497	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. 2014 , 55, 243-55		70
1496	Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. 2014 , 99, 54-9		39
1495	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. 2014 , 99, e185-7		23
1494	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. 2014 , 6, 69-81		24
1493	High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions. 2014 , 99, e257-9		22
1492	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly complicated by the onset of acute myeloid leukemia. 2014 , 53, 51-6		2
1491	Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. <i>Blood</i> , 2014 , 123, 3327-35	2.2	45
1490	CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. <i>Blood</i> , 2014 , 123, 356-65	2.2	132
1489	Immune evasion by oncogenic proteins of acute myeloid leukemia. <i>Blood</i> , 2014 , 123, 1535-43	2.2	37
1488	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. <i>Blood</i> , 2014 , 123, 3855-63	2.2	265
1487	Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. <i>Blood</i> , 2014 , 124, 1127-35	2.2	41
1486	Outcome of patients with abn(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014 , 123, 2960-7	2.2	51
1485	Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. <i>Blood</i> , 2014 , 123, 4027-36	2.2	60
1484	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. <i>Blood</i> , 2014 , 124, 1426-33	2.2	172
1483	How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. <i>Blood</i> , 2014 , 124, 3858-69	2.2	53
1482	Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. <i>Blood</i> , 2014 , 124, 3441-9	2.2	260
1481	Management and orphan drug development for acute myeloid leukemia. 2014 , 2, 441-451		

1480	microRNA-125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis. 2014 , 9, 1909-16	20
1479	Next generation sequencing of acute myeloid leukemia: influencing prognosis. 2015 , 16 Suppl 1, S5	33
1478	The role of multiparametric flow cytometry in the detection of minimal residual disease in acute leukaemia. 2015 , 47, 609-21	6
1477	Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. 2015 , 100, 1172-9	70
1476	HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation. 2015 , 10, 3137-3144	8
1475	Epigenetic alterations in acute myeloid leukemias. 2015 , 282, 1786-800	29
1474	Outcome of patients with multiple myeloma and hypotension during high-dose chemotherapy. 2015 , 90, E125-7	2
1473	Plasma cell leukemia: from biology to treatment. 2015 , 95, 16-26	27
1472	Acute myeloid leukemia in the pregnant patient. 2015 ,	4
1471	Post-remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age \geq 5 years: a retrospective analysis of the Rete Ematologica Lombarda. 2015 , 90, E123-5	2
1470	Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. 2015 , 106, 1590-5	29
1469	Acute Myeloid Leukaemia. 2015 , 352-370	2
1468	Connexin expression in human acute myeloid leukemia cells: identification of patient subsets based on protein and global gene expression profiles. 2015 , 35, 645-52	8
1467	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. 2015 , 100, e351-3	22
1466	Acute Myeloid Leukemia. 2015 , 89-100	1
1465	Retinoic Acid in Acute Myeloid Leukemias. 2015 , 543-555	1
1464	Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy. 2015 , 22, 49-65	6
1463	Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. <i>Blood</i> , 2015 , 125, 133-9	2.2 64

1462	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015 , 126, 2062-9	2.2	71
1461	Prognostic significance of the gene expression in adult patients with acute myeloid leukemia: A meta-analysis. 2015 , 3, 880-888		15
1460	[The Cutting-edge of Medicine; Genetic alterations and their prognostic implications in acute myeloid leukemia]. 2015 , 104, 1180-8		
1459	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. 2015 , 100, e409-11		9
1458	Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report. 2015 , 133, 271-4		2
1457	High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia. 2015 , 100, e223-5		11
1456	The indicator of hypoxia in acute leukemia: Ischemia-modified albumin. 2015 , 15, 559-65		6
1455	Akute myeloische Leukämie. 2015 , 10, 42-51		
1454	Case study interpretation--Fort Lauderdale: Case 3. 2015 , 88, 404-7		1
1453	ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome. 2015 , 90, 784-9		14
1452	An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts. 2015 , 170, 80-4		10
1451	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. 2015 , 170, 305-22		28
1450	Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome. 2015 , 95, 498-506		28
1449	An integrated approach of gene expression and DNA-methylation profiles of WNT signaling genes uncovers novel prognostic markers in acute myeloid leukemia. 2015 , 16 Suppl 4, S4		16
1448	Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations. 2015 , 90, 992-7		17
1447	Health care utilization and end-of-life care for older patients with acute myeloid leukemia. 2015 , 121, 2840-8		79
1446	Leukemia diagnosis: today and tomorrow. 2015 , 95, 365-73		17
1445	Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology. 2015 , 22, 158-66		12

1444	Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. 2015 , 54, 489-499	10
1443	The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. 2015 , CD010432	22
1442	Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia. 2015 , 90, 1159-64	17
1441	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. 2015 , 137, 2083-92	14
1440	The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia. 2015 , 40, 555-560	3
1439	31e Congrès de la Société française d'hématologie. 2015 , 21, 68-82	
1438	Diagnostik von myelodysplastischen Syndromen (MDS) und akuten myeloischen Leukämien (AML). 2015 , 39,	
1437	. 2015 ,	8
1436	Prognostic value of brain and acute leukemia cytoplasmic gene expression in egyptian children with acute myeloid leukemia. 2015 , 7, e2015033	4
1435	Individualized Treatment Strategy with Small-Molecular Inhibitors in Acute Myeloid Leukemia with Concurrent FLT3-ITD and FLT3-TKD Mutation. 2015 , 5,	2
1434	Gene Mutations in Acute Myeloid Leukemia Incidence, Prognostic Influence, and Association with Other Molecular Markers. 2015 ,	2
1433	Volasertib for AML: clinical use and patient consideration. 2015 , 8, 1761-71	10
1432	Non-leukemic myeloid sarcoma involving the vulva, vagina, and cervix: a case report and literature review. 2015 , 8, 3707-13	9
1431	Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. 2015 , 6, 30212-21	29
1430	Association between Treatment Response and Potential Indicators of Efficacy and Safety in a Phase III Trial of Decitabine in Older Patients with Acute Myeloid Leukemia. 2015 , 06,	2
1429	Should a More Personalized Approach be Applied to Hematopoietic Stem-Cell Transplantation?. 2015 , 05,	
1428	Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients. 2015 , 4, 441-59	12
1427	Molecular Genetic Markers in Acute Myeloid Leukemia. 2015 , 4, 460-78	50

1426	Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies. 2015 , 5, 280		27
1425	Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32). 2015 , 10, e0132736		14
1424	G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound. 2015 , 10, e0136878		22
1423	[Acute myeloid leukemia and translocation (8; 16) (p11; p13), the first Moroccan case of a distinct clinical-biological entity]. 2015 , 21, 147		0
1422	Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?. 2015 , 6, 18845-62		14
1421	Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?. 2015 , 22, 123-31		3
1420	APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. 2015 , 21, 3934-45		28
1419	The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy. 2015 , 102, 35-40		4
1418	Cell chemotaxis on paper for diagnostics. 2015 , 87, 5505-10		14
1417	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. <i>Blood</i> , 2015 , 126, 291-9	2.2	693
1416	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. 2015 , 28, 965-76		20
1415	BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4. 2015 , 29, 2248-56		25
1414	Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. 2015 , 50, 1063-8		31
1413	Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. 2015 , 6, 25-9		4
1412	DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. 2015 , 15, 430		42
1411	Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. 2015 , 90, 483-6		19
1410	Minimal residual disease in acute myeloid leukemia--current status and future perspectives. 2015 , 10, 132-44		24
1409	Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia. 2015 , 94, 1337-45		3

1408	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. 2015 , 21, 1405-1412	20
1407	Survival of patients with mixed phenotype acute leukemias: A large population-based study. 2015 , 39, 606-16	34
1406	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. 2015 , 19, 1187-202	11
1405	Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. 2015 , 2, e427-36	61
1404	Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics. 2015 , 8, 143-9	3
1403	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Hematologic Working Party of the European Society for Blood and Marrow Transplantation. 2015 , 15, 103-11	33
1402	Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy. 2015 , 10, 122	3
1401	Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data. 2015 , 39, 892-900	20
1400	Chromosome Abnormalities in Acute Myeloid Leukaemia and Their Clinical Importance. 2015 , 275-317	2
1399	Update on recurrent genetic aberrations in acute myeloid leukemia. 2015 , 4, 179-190	1
1398	The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. 2015 , 15, 530-541	41
1397	Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length. 2015 , 5, e336	45
1396	Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia. 2015 , 5, e339	11
1395	Akute myeloische Leukämie. 2015 , 18, 30-37	
1394	Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. 2015 , 21, 1754-60	11
1393	Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia. 2015 , 8, 106-14	4
1392	Overview: A New Era of Cancer Genome in Myeloid Malignancies. 2015 , 89 Suppl 1, 1-3	1
1391	Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. 2015 , 29, 377-86	47

1390	Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. 2015 , 33, 340-8	67
1389	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications. 2015 , 39, 88-91	16
1388	Genetics and Classification of Acute Myeloid Leukemia. 2015 , 1-25	
1387	Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study. 2015 , 56, 1353-61	12
1386	PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia. 2015 , 29, 1202-6	8
1385	Retinoic acid receptors: from molecular mechanisms to cancer therapy. 2015 , 41, 1-115	204
1384	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. 2015 , 8, 43-56	21
1383	High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT. 2015 , 50, 341-7	11
1382	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. 2015 , 39, 296-306	37
1381	Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation. 2015 , 21, 546-51	19
1380	Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. 2015 , 90, E77-9	55
1379	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. 2015 , 90, E80-5	59
1378	Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis. 2015 , 94, 929-38	12
1377	miR-21 is overexpressed in NPM1-mutant acute myeloid leukemias. 2015 , 39, 221-8	20
1376	Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná 2015 , 37, 21-7	16
1375	Acute myeloid leukemia in the pregnant patient. 2015 , 95, 124-36	12
1374	Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. 2015 , 21, S3-10	4
1373	One day at a time: improving the patient experience during and after intensive chemotherapy for younger and older AML patients. 2015 , 39, 192-7	8

1372	The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro. 2015 , 39, 257-62	18
1371	Cellular origin of prognostic chromosomal aberrations in AML patients. 2015 , 29, 1785-9	7
1370	Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. 2015 , 29, 1243-52	26
1369	LukS-PV, a component of Panton-Valentine leukocidin, exerts potent activity against acute myeloid leukemia in vitro and in vivo. 2015 , 61, 20-8	9
1368	Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?. 2015 , 21, 713-9	26
1367	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. 2015 , 100, 324-30	67
1366	High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia. 2015 , 137, 1058-65	30
1365	Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. 2015 , 21, 373-8	17
1364	Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group. 2015 , 21, 653-60	125
1363	Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. 2015 , 15, 236-44	19
1362	Identifying the similarities and differences between single nucleotide polymorphism array (SNPa) analysis and karyotyping in acute myeloid leukemia and myelodysplastic syndromes. 2015 , 37, 48-54	9
1361	Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia. 2015 , 169, 199-210	21
1360	A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. 2015 , 29, 1069-75	46
1359	A Review of Mathematical Models for Leukemia and Lymphoma. 2015 , 16, 1-6	16
1358	You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. 2015 , 29, 517-25	58
1357	Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. 2015 , 39, 183-91	32
1356	Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. 2015 , 94, 23-34	10
1355	Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. 2015 , 33, 403-10	60

1354	Time to reconsider the role of allogeneic transplantation for patients with acute myeloid leukemia and NPM1 mutation?. 2015 , 33, 381-2	1
1353	Mutant Enrichment with 3'-Modified Oligonucleotides (MEMO)-Quantitative PCR for Detection of NPM1 Mutations in Acute Myeloid Leukemia. 2015 , 29, 361-5	2
1352	The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features. 2015 , 94, 35-43	13
1351	Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. 2015 , 29, 1555-1563	34
1350	Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate. 2015 , 8, 5	1
1349	Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). 2015 , 29, 2375-81	29
1348	High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. 2015 , 10, e0128410	36
1347	Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations. 2015 , 144, 19-28	6
1346	Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. 2015 , 144, 78-86	11
1345	CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?. 2015 , 7, 545-61	21
1344	Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Soci� Francaise de Greffe de Moelle et de Th�rapie Cellulaire. 2015 , 21, 1059-67	19
1343	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. 2015 , 16, 1025-1036	113
1342	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. 2015 , 43, 858-868.e7	26
1341	Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. 2015 , 79, 685-91	2
1340	Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis. 2015 , 43, 609-24	39
1339	MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. 2015 , 43, 794-802.e4	15
1338	Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. 2015 , 50, 1004-1006	1
1337	MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine. 2015 , 32, 206	13

1336	Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia. 2015 , 52, 249-55	3
1335	Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. 2015 , 9, 1217-1220	3
1334	Isolated primary intracranial myeloid sarcoma with neuromeningeal infiltration: A case report. 2015 , 9, 1647-1650	6
1333	Tropical Hemato-Oncology. 2015 ,	2
1332	High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. 2015 , 39, 945-9	20
1331	High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia. 2015 , 36, 9711-6	13
1330	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. 2015 , 21, 1425-30	9
1329	Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML. 2015 , 5, 11295	144
1328	Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?. 2015 , 52, 223-31	7
1327	Insights into cell ontogeny, age, and acute myeloid leukemia. 2015 , 43, 745-55	19
1326	Clinical impact of SNP of P53 genes pathway on the adult AML patients. 2015 , 20, 328-35	7
1325	Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?. 2015 , 8, 135-8	19
1324	Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. 2015 , 56, 1718-22	16
1323	Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. 2015 , 2, e204-11	14
1322	Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. 2015 , 52, 150-64	46
1321	Heme oxygenase-1 suppresses the apoptosis of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway. 2015 , 39, 544-52	26
1320	ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate. 2015 , 36, 7599-606	8
1319	Nouvelles approches thérapeutiques dans les leucémies aiguës myéloïdes. 2015 , 2015, 65-73	

1318	AML versus ICU: outcome of septic AML patients in an intensive care setting. 2015 , 141, 1645-51		6
1317	Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. 2015 , 90, 515-23		38
1316	How I treat refractory and early relapsed acute myeloid leukemia. <i>Blood</i> , 2015 , 126, 319-27	2.2	185
1315	STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. 2015 , 8, 29-41		27
1314	AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells. 2015 , 8, 18		21
1313	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. 2015 , 29, 1891-900		158
1312	How I treat hyperleukocytosis in acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 3246-52	2.2	110
1311	Cytosine modifications in myeloid malignancies. 2015 , 152, 42-53		11
1310	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015 , 125, 3236-45		90
1309	Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. 2015 , 143, 873-8		16
1308	Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy. 2015 , 39, 779-85		33
1307	ACUTE LEUKEMIAS XV. 2015 , 94, 1-102		12
1306	Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis. 2015 , 50, 706-14		19
1305	Akute Leukämien des Erwachsenen. 2015 , 21, 533-550		
1304	Immunotherapy for Acute Myeloid Leukemia. 2015 , 52, 207-14		39
1303	Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?. 2015 , 56, 3005-7		1
1302	Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. <i>Blood</i> , 2015 , 125, 3956-62	2.2	268
1301	Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). 2015 , 26, 1434-40		9

1300	Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. 2015 , 22, 85-91	27
1299	Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. 2015 , 101, 543-53	13
1298	Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis. 2015 , 121, 2004-12	46
1297	Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. 2015 , 50, 485-92	17
1296	[Acute myeloid leukemia]. 2015 , 56, 354-63	5
1295	The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. 2015 , 90, 504-10	26
1294	Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. 2015 , 21, 3187-95	9
1293	Place de la biologie moléculaire pour le diagnostic et le suivi des leucémies aiguës. 2015 , 2015, 51-64	1
1292	Place de la cytogénétique dans le diagnostic des leucémies aiguës myéloïdes. 2015 , 2015, 43-49	
1291	Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication. 2015 , 8, 299-313	13
1290	Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. 2015 , 141, 1661-8	7
1289	Fruit extract from a <i>Sechium edule</i> hybrid induce apoptosis in leukaemic cell lines but not in normal cells. 2015 , 67, 250-7	17
1288	Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy. 2015 , 139, 1215-23	32
1287	RETRACTED ARTICLE: 5-Azacitidine for treating acute myelogenous leukemia. 2015 , 3, 1197-1207	1
1286	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. 2015 , 100, e254-6	3
1285	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. 2015 , 100, e196-9	12
1284	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 2015 , 33, 4167-75	111
1283	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. 2015 , 39, 1443-7	8

1282	Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. 2015 , 100, 331-5	19
1281	Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia. 2015 , 56, 2326-30	15
1280	Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. 2015 , 20, 1404-12	25
1279	Toward a better management of older patients with acute myeloid leukemia. 2015 , 11, 715-8	2
1278	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. 2015 , 56, 3116-23	19
1277	Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. 2015 , 94, 1797-806	8
1276	Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia. 2015 , 28, 90-7	8
1275	Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. 2015 , 28, 133-40	3
1274	Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. 2015 , 56, 622-9	9
1273	Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. 2015 , 56, 3135-42	5
1272	Novel STAT5B-RARA fusion transcript in acute promyelocytic leukemia: identification and treatment response. 2015 , 56, 2731-4	11
1271	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. 2015 , 169, 694-700	71
1270	Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis. 2015 , 94, 439-48	29
1269	The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes. 2015 , 37 Suppl 1, 115-21	38
1268	The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. 2015 , 37 Suppl 1, 122-32	7
1267	Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcome. 2015 , 8, 28-33	24
1266	Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. 2015 , 170, 590-3	11
1265	Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. 2015 , 62, 65-71	17

1264	The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. 2015 , 5, e352	15
1263	RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML. 2015 , 64, 1505-15	3
1262	Whole-exome sequencing enhances prognostic classification of myeloid malignancies. 2015 , 58, 104-113	9
1261	Acute Leukemia. 2015 , 279-289	
1260	Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML. 2015 , 102, 553-7	16
1259	Assessment of Molecular Markers in AML Patients: A Hospital-Based Study in Lebanon. 2015 , 15 Suppl, S80-4	1
1258	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. 2015 , 28, 1014-22	18
1257	Mass Cytometry: A High-Throughput Platform to Visualize the Heterogeneity of Acute Myeloid Leukemia. 2015 , 5, 912-4	4
1256	Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets. 2015 , 8, 315-27	8
1255	Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML. 2015 , 144, 484-92	11
1254	Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. 2015 , 50, 1495-502	33
1253	Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process. 2015 , 16, 37	22
1252	Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. 2015 , 39, 1084-92	23
1251	Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor. 2015 , 53, 23-9	17
1250	Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. 2015 , 50, 1542-50	55
1249	Acute Myeloid Leukemia. 2015 , 373, 1136-52	1718
1248	[Acute leukemia in adults]. 2015 , 36, 503-17; quiz 518-9	4
1247	Allogeneic Transplantation for Unfavorable-Risk Acute Myeloid Leukemia. 2015 , 15 Suppl, S70-2	1

1246	How Do Pretransplantation Peripheral Blood Counts Inform Us about Post-Transplantation Outcomes in Acute Myeloid Leukemia?. 2015 , 21, 1340-2	
1245	Monitoring of WT1 and its target gene IRF8 expression in acute myeloid leukemia and their significance. 2015 , 37, e67-71	2
1244	An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. 2015 , 11, 53-65	2
1243	TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome. 2015 , 94, 355-62	11
1242	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. 2015 , 101, 243-54	18
1241	Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. 2015 , 23, 184-91	226
1240	Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. 2015 , 94, 449-55	7
1239	Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. 2015 , 15, 13-21	15
1238	Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. 2015 , 29, 1041-50	100
1237	Azacitidine for the treatment of relapsed and refractory AML in older patients. 2015 , 39, 124-30	51
1236	Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia. 2015 , 16, 83-8	27
1235	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. 2015 , 21, 8-15	36
1234	Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. 2015 , 100, 336-44	70
1233	Molecular genetic biomarkers in myeloid malignancies. 2015 , 139, 594-601	10
1232	Label-free imaging and identification of typical cells of acute myeloid leukaemia and myelodysplastic syndrome by Raman microspectroscopy. 2015 , 140, 1054-64	37
1231	Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. 2015 , 21, 559-64	42
1230	Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. 2015 , 29, 312-20	106
1229	BRCA1, PARP1 and H2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 2015 , 1852, 462-72	44

1228	Progress in acute myeloid leukemia. 2015 , 15, 139-51	33
1227	Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. 2015 , 100, 214-22	38
1226	Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. 2015 , 35, 586-618	101
1225	Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. 2015 , 28, 706-14	89
1224	Management of Hematological Cancer in Older People. 2015 ,	
1223	Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. 2015 , 90, 125-31	6
1222	High receptor tyrosine kinase (FLT3, KIT) transcript versus anti-apoptotic (BCL2) transcript ratio independently predicts inferior outcome in pediatric acute myeloid leukemia. 2015 , 54, 56-64	3
1221	Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. 2015 , 29, 137-44	142
1220	Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study. 2015 , 56, 1033-42	27
1219	Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. 2015 , 29, 567-75	54
1218	Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia. 2015 , 168, 268-73	11
1217	Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. 2015 , 56, 1012-9	11
1216	Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients. 2015 , 90, E22-4	13
1215	Jagged-1: a new promising factor associated with favorable prognosis in patients with acute myeloid leukemia. 2015 , 56, 401-6	10
1214	The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia. 2015 , 31, 21-8	8
1213	Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML. 2015 , 50, 74-81	21
1212	Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. 2015 , 29, 11-9	138
1211	. 2016 ,	2

1210	Immunophenotyping of Acute Leukemias [From Biology to Clinical Application. 2016,	3
1209	Test Guidelines for Initial Diagnosis of Hematologic Neoplasms. 2016, 6, 1	2
1208	Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland. 2016, 12, 120-8	3
1207	Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A. 2016, 36, 399-404	7
1206	Novel diagnostic tools: implication for the diagnosis, prognosis and understanding of haematological malignancies. 2016, 22, 66-72	
1205	Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease. 2016, 51, 175-180	1
1204	Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?. 2016, 35, e302-12	6
1203	Acute myeloid leukemia masquerading as hepatocellular carcinoma. 2016, 7, E31-5	5
1202	Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématoologique (GFCH). 2016, 74, 535-546	3
1201	Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications. 2016, 8, e2016052	14
1200	Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. 2016, 2016, 7625827	6
1199	Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. 2016, 11, e0159477	41
1198	The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia. 2016, 33, 135-40	7
1197	Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. 2016, 11, 641-60	30
1196	A comparative study of idarubicin 12 mg/m(2) and 8 mg/m(2) combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients. 2016, 9, 985-91	1
1195	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. 2016, 7, 94	22
1194	A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators. 2016, 7, 205	22
1193	Acute Myeloid Leukemia: A Concise Review. 2016, 5,	161

1192	18β-Glycyrrhetic Acid Induces Apoptosis of HL-60 Human Leukemia Cells through Caspases- and Mitochondria-Dependent Signaling Pathways. 2016 , 21,	26
1191	A Rare Case of Acute Myeloid Leukemia with a t(2;3) Chromosomal Translocation Characterized by Thrombophilia and Chemoresistance. 2016 , 56, 64-8	
1190	Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia. 2016 , 11, e0150632	23
1189	Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. 2016 , 11, e0146614	36
1188	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. 2016 , 11, e0153016	9
1187	Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. 2016 , 11, e0164587	23
1186	IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. 2016 , 7, 171-80	118
1185	MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients. 2015 , 6, 324	12
1184	EM23, A Natural Sesquiterpene Lactone from <i>Elephantopus mollis</i> , Induces Apoptosis in Human Myeloid Leukemia Cells through Thioredoxin- and Reactive Oxygen Species-Mediated Signaling Pathways. 2016 , 7, 77	27
1183	Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. 2016 , 17,	48
1182	Low dose cytarabine monotherapy for acute myeloid leukaemia. 2016 ,	
1181	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. 2016 , 7, 43027-43038	29
1180	High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?. 2016 , 34, 28-35	10
1179	Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. 2016 , 91, 302-7	39
1178	Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. 2016 , 91, 800-5	23
1177	Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?. 2016 , 23, 102-7	2
1176	Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia. 2016 , 47, 149-60	12
1175	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. 2016 , 12, 293-302	30

1174	Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. 2016 , 5, e1196308	32
1173	TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. 2016 , 172, 914-22	54
1172	Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy. 2016 , 173, 49-58	23
1171	A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. 2016 , 174, 700-10	36
1170	Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study. 2016 , 96, 236-44	6
1169	Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. 2016 , 91, 227-33	30
1168	Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy. 2016 , 96, 586-92	1
1167	The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease. 2016 , 97, 471-478	4
1166	Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia. 2016 , 55, 553-67	11
1165	Review: Aberrant EVI1 expression in acute myeloid leukaemia. 2016 , 172, 870-8	46
1164	Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. 2016 , 91, E302-3	2
1163	The prognostic value of hematogones in patients with acute myeloid leukemia. 2016 , 91, 566-70	6
1162	'Acute myeloid leukemia: a comprehensive review and 2016 update'. 2016 , 6, e441	542
1161	Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches. 2016 , 9, 851-859	2
1160	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 2016 , 122, 1880-7	26
1159	Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy. 2016 , 91, 193-8	18
1158	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 2016 , 91, 227-32	29
1157	Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. 2016 , 91, 406-9	11

1156	High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. 2016 , 91, 755-62	16
1155	Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. 2016 , 97, 278-87	10
1154	Aberrant splicing and drug resistance in AML. 2016 , 9, 85	34
1153	Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). 2016 , 101, 1516-1523	10
1152	The role of the proteasome in AML. 2016 , 6, e503	24
1151	Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia. 2016 , 6, 35561	19
1150	Why do subjects on clinical trials discontinue therapy? Do we really know?. 2016 , 51, 19-21	
1149	A three-gene expression-based risk score can refine the European LeukemiaNet AML classification. 2016 , 9, 78	14
1148	Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives. 2016 , 5, 143-164	5
1147	Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML. 2016 , 64, 1252-1260	6
1146	The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. 2016 , 6, 20508	25
1145	Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis. 2016 , 6, e507	4
1144	High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia. 2016 , 14, 55-64	42
1143	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. 2016 , 101, 839-45	19
1142	inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice. <i>Blood</i> , 2016 , 128, 2130-2134	2.2 31
1141	IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. 2015 , 5, 18411	32
1140	Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. 2016 , 7, e2497	11
1139	Mutations in AML: prognostic and therapeutic implications. 2016 , 2016, 348-355	77

1138	A 17-gene stemness score for rapid determination of risk in acute leukaemia. 2016 , 540, 433-437	369
1137	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. 2016 , 8, 368ra171	102
1136	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. 2016 , 2016, 24-32	18
1135	Ophthalmic manifestations of leukemia. 2016 , 27, 545-551	50
1134	Leucemias agudas. 2016 , 12, 1201-1212	
1133	Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). 2016 , 44, 40-4	14
1132	Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha. 2016 , 22, 1125-1132	16
1131	Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms. 2016 , 11, 11	61
1130	Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study. 2016 , 95, 1223-32	10
1129	Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy. 2016 , 351, 473-9	6
1128	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. 2016 , 3, e276-83	16
1127	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. 2016 , 95, 625-35	11
1126	Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. 2016 , 76, 3644-54	36
1125	The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. 2016 , 21, 692-700	32
1124	A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. 2016 , 42, 82-7	11
1123	Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. 2016 , 29, 727-34	6
1122	Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. 2016 , 51, 994-6	4
1121	Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer. 2016 , 27, 143-6	7

1120	Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. 2016 , 42, 186-98		60
1119	Characterization of NPM1, FLT3, and IDH1 mutations in adult patients with acute myeloid leukemia: a Brazilian cohort study. 2016 , 57, 2901-2904		1
1118	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. 2016 , 57, 1205-7		1
1117	Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. 2016 , 101, 248-55		15
1116	Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia. 2016 , 45, 47-52		4
1115	Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy. 2016 , 46, 45-50		11
1114	Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy. 2016 , 95, 1051-7		11
1113	Emerging strategies for the treatment of older patients with acute myeloid leukemia. 2016 , 95, 1583-93		12
1112	A new model to predict remission status in AML patients based on day 14 bone marrow biopsy. 2016 , 46, 69-73		11
1111	RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. 2016 , 30, 2160-2168		121
1110	Extramedullary acute myelogenous leukemia. 2016 , 30, 333-9		38
1109	Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium. 2016 , 46, 26-9		7
1108	Hematopoietic stem cell transplantation for patients with AML in first complete remission. <i>Blood</i> , 2016 , 127, 62-70	2.2	167
1107	An update of current treatments for adult acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 53-61	2.2	313
1106	Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. <i>Blood</i> , 2016 , 128, e1-9	2.2	36
1105	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. <i>Blood</i> , 2016 , 127, 2890-902	2.2	69
1104	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 2451-9	2.2	136
1103	Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. <i>Blood</i> , 2016 , 128, 686-98	2.2	314

1102	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. <i>Blood</i> , 2016 , 128, 763-73	2.2	37
1101	Hospital volume and acute myeloid leukemia mortality in Medicare beneficiaries aged 65 years and older. <i>Blood</i> , 2016 , 128, 872-4	2.2	7
1100	Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. 2016 , 50, 385-393		13
1099	Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. 2016 , 9, 79		28
1098	Acute myeloid leukaemia. 2016 , 133-202		
1097	Leukapheresis in patients newly diagnosed with acute myeloid leukemia. 2016 , 55, 216-220		15
1096	Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. 2016 , 35, 2399-2416	11	
1095	Acute Myeloid Leukemia: How Do We Measure Success?. 2016 , 11, 528-536		8
1094	Just 1 test to diagnose AML?!. <i>Blood</i> , 2016 , 128, 8-10	2.2	1
1093	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. 2016 , 22, 1961-1967		25
1092	A clinical challenge: Treatment of acute myeloid leukemia in a Jehovah's Witness. 2016 , 38, 358-360		2
1091	[Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients]. 2016 , 147, 185-191		1
1090	RUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case report. 2016 , 36, 2481-2488		5
1089	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. 2016 , 95, 1931-1942		52
1088	Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. 2016 , 3, e330-9		21
1087	Blood transfusion for patients with newly diagnosed acute myeloid leukaemia undergoing induction chemotherapy in a large medical centre in China: a retrospective analysis. 2016 , 26, 383-384		
1086	Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia. 2016 , 101, 448-57		8
1085	Novel therapeutic options in Acute Myeloid Leukemia. 2016 , 6, 39-49		25

1084	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. 2016 , 16, 652	10
1083	Monosomal karyotype is not a predictor of dismal outcome in childhood de novo acute myeloid leukemia. 2016 , 50, 57-62	6
1082	Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia. 2016 , 175, 904-916	13
1081	Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations. 2016 , 101, 1074-81	12
1080	Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. 2016 , 175, 226-236	43
1079	Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse. 2016 , 24, 73-80	5
1078	Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis. 2016 , 64, 1225-1236	10
1077	Panobinostat for the treatment of acute myelogenous leukemia. 2016 , 25, 1117-31	17
1076	Hematopoietic Cell Transplantation from Unrelated Donors. 2016 , 505-520	
1075	Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia. 2016 , 563-577	
1074	Relapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation. 2016 , 836-844	
1073	Cancer treatment and survivorship statistics, 2016. 2016 , 66, 271-89	3256
1072	Autologous Hematopoietic Stem Cell Transplantation for Adults With Acute Myeloid Leukemia. 2016 , 48, 1814-7	6
1071	Acute Myeloid Leukemia: Past, Present, and Prospects for the Future. 2016 , 16 Suppl, S25-9	21
1070	Development of a NanoString assay to detect leukemogenic fusion transcripts in acute myeloid leukemia. 2016 , 38, 663-673	7
1069	Acute myeloid leukemia--major progress over four decades and glimpses into the future. 2016 , 91, 131-45	67
1068	Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. 2016 , 174, 526-35	8
1067	Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?. 2016 , 96, 211-21	16

1066	Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. 2016 , 91, 1221-1226		8
1065	The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia. 2016 , 172, 573-80		14
1064	Stanniocalcin1 gene expression in patients with acute leukemia: impact on response to therapy and disease outcome. 2016 , 38, 81-9		3
1063	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. 2016 , 16, 616-624		8
1062	Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia. 2016 , 44, 1039-1043.e10		9
1061	Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine?. 2016 , 10, 935-8		1
1060	A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). 2016 , 48, 92-100		35
1059	Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. 2016 , 122, 3821-3830		56
1058	Celecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome function. 2016 , 84, 1551-1557		15
1057	Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥80 years) who benefit from intensive post-induction consolidation therapy. 2016 , 91, 1239-1245		9
1056	The Time to Clearance of Peripheral Blood Blasts Predicts Complete Remission and Survival in Chinese Adults with Acute Myeloid Leukemia. 2016 , 135, 217-23		2
1055	Venous ulcers and risk of occult hematological or other cancers: a nationwide cohort study. <i>Blood</i> , 2016 , 128, 874-7	2.2	2
1054	Varying responses of PML-RARA with different genetic mutations to arsenic trioxide. <i>Blood</i> , 2016 , 127, 243-50	2.2	16
1053	Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 1449-58	2.2	81
1052	Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. 2016 , 6, e469		29
1051	Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies. 2016 , 420, 121-8		12
1050	Acute myeloid leukemia: 2016 Update on risk-stratification and management. 2016 , 91, 824-46		43
1049	Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report. 2016 , 11, 145-7		1

1048	Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. 2016 , 78, 1051-1058	12
1047	Acute myeloid leukaemia. 2016 , 2, 16010	159
1046	Epidemiology, pathogenesis, and etiology of acute leukemia. 2016 , 3-13	5
1045	Clinical manifestations and diagnosis. 2016 , 15-23	1
1044	Diagnostic criteria, classification, and prognosis of acute leukemias. 2016 , 25-39	
1043	Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients. 2016 , 147, 185-191	
1042	Role of HOTAIR in the diagnosis and prognosis of acute leukemia. 2016 , 36, 3113-3122	40
1041	An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. 2016 , 101, 1351-1358	51
1040	Handbook of Acute Leukemia. 2016 ,	
1039	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. 2016 , 8, 357ra123	403
1038	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. 2016 , 9, 101	56
1037	CHK1 as a therapeutic target to bypass chemoresistance in AML. 2016 , 9, ra90	49
1036	Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. 2016 , 101, 20-5	40
1035	A novel mechanism of NPM1 cytoplasmic localization in acute myeloid leukemia: the recurrent gene fusion NPM1-HAUS1. 2016 , 101, e287-90	9
1034	Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. 2016 , 5, 3068-3076	8
1033	Clinical and laboratory characteristics of acute myeloid leukaemia (AML) at relapse and the risk of acute incapacitation. 2016 , 69, 275-6	
1032	Diagnostics of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). 2016 , 39,	
1031	Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. 2016 , 6, e449	50

1030	Personalisierte Medizin in der Hämatologie am Beispiel der akuten myeloischen Leukämie. 2016 , 28, 435-442	
1029	shRNA-mediated RPS15A silencing inhibits U937 acute myeloid leukemia cell proliferation and enhances apoptosis. 2016 , 13, 4400-6	10
1028	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. 2016 , 14, 787-92	4
1027	Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response. 2016 , 95, e5356	4
1026	Argatroban monitoring: aPTT versus chromogenic assay. 2016 , 91, E303-4	4
1025	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. 2016 , 122, 304-11	89
1024	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. 2016 , 55, 322-7	6
1023	Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. 2016 , 172, 238-45	22
1022	Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. 2016 , 172, 384-91	49
1021	Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis. 2016 , 97, 517-527	11
1020	Genomic Classification and Prognosis in Acute Myeloid Leukemia. 2016 , 374, 2209-2221	1999
1019	Harnessing the immune system in acute myeloid leukaemia. 2016 , 103, 62-77	61
1018	[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. 2016 , 59, 444-53	0
1017	Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes. 2016 , 101, 607-16	16
1016	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. 2016 , 22, 792-9	217
1015	Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. 2016 , 145, 769-77	29
1014	Unfavorable-risk acute myeloid leukemia dissected. 2016 , 23, 144-9	3
1013	Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. 2016 , 6, e390	41

1012	Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC). 2016 , 57, 2937-2941	1
1011	Treatment of elderly and very old patients with AML. 2016 , 9, 4-7	
1010	Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. 2016 , 46, 61-8	5
1009	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. 2016 , 9, 39	28
1008	Impact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome - Study protocol of a randomized placebo-controlled trial. 2016 , 49, 1-5	13
1007	Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. 2016 , 11, 517-25	18
1006	Spectrum of mucocutaneous manifestations in an Asian cohort of patients with leukemia. 2016 , 55, 893-7	1
1005	New drugs in acute myeloid leukemia. 2016 , 27, 770-8	56
1004	Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. 2016 , 142, 317-24	10
1003	Assessment of Minimal Residual Disease in Standard-Risk AML. 2016 , 374, 422-33	500
1002	Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?. 2016 , 9, 335-50	19
1001	Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. 2016 , 7, 3-16	51
1000	Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. 2016 , 9, 447-69	9
999	Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System. 2016 , 56, 10-20	8
998	Karyotype complexity and prognosis in acute myeloid leukemia. 2016 , 6, e386	49
997	Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. 2016 , 9, 351-60	6
996	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. 2016 , 22, 3057-66	154
995	Great expectations in acute myeloid leukemia. 2016 , 12, 289-92	

994	Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia. 2016 , 57, 2140-9	7
993	Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience. 2016 , 16, e21-6	5
992	In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. 2016 , 30, 1582-6	34
991	Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations. 2016 , 34, e123-5	1
990	X-ray characterization and in vitro biological evaluation of 1-(4-amidophenyl)-3-(4-acetylphenyl)triazene and the gold(I) triazenide complex {Au(I)[RPhNNNPhR?][PPh3]} [R = (C O)NH2, R? = (C O)CH3]. 2016 , 441, 78-85	6
989	Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML. 2016 , 51, 604-6	12
988	Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. 2016 , 51, 610-1	144
987	AML multi-gene panel testing: A review and comparison of two gene panels. 2016 , 212, 372-80	3
986	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. 2016 , 3, e186-95	276
985	Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. 2016 , 30, 1485-92	79
984	A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia. 2016 , 172, 401-11	14
983	Hypomethylating agents for adult patients with acute myeloid leukaemia. 2016 ,	
982	Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients. 2016 , 5, 265-74	20
981	Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. 2016 , 96, 175-80	12
980	Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. 2016 , 22, 982-990	34
979	Radioimmunotherapy for Treatment of Acute Leukemia. 2016 , 46, 135-46	24
978	Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis. 2016 , 42, 47-51	11
977	Simultaneous detection of mutations and copy number variation of NPM1 in the acute myeloid leukemia using multiplex ligation-dependent probe amplification. 2016 , 786, 14-26	10

976	Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. 2016 , 30, 1230-6	29
975	High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia. 2016 , 135, 55-64	5
974	Next-Generation Sequencing: Principles for Clinical Application. 2016 , 889-909	
973	Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. 2016 , 57, 2281-8	25
972	The European Hematology Association Roadmap for European Hematology Research: a consensus document. 2016 , 101, 115-208	46
971	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. 2016 , 34, 329-36	270
970	GFI1 as a novel prognostic and therapeutic factor for AML/MDS. 2016 , 30, 1237-45	25
969	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. 2016 , 76, 2082-6	19
968	Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. 2016 , 30, 1456-64	107
967	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. 2016 , 9, 433-45	7
966	Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. 2016 , 9, 143-63	10
965	Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKP46 Activating Receptors on NK Cells in Acute Myeloid Leukemia. 2016 , 47, 55-64	18
964	The safety of treatment options for elderly people with acute myeloid leukemia. 2016 , 15, 635-45	2
963	The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia. 2016 , 16, 377-82	3
962	Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. 2016 , 30, 1781-4	11
961	Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia. 2016 , 34, 300-2	7
960	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. 2016 , 51, 194-8	16
959	Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study. 2016 , 57, 1575-84	10

958	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. 2016 , 95, 301-10	19
957	Molecular therapy for acute myeloid leukaemia. 2016 , 13, 305-18	86
956	Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. 2016 , 30, 782-8	18
955	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. 2016 , 95, 191-9	73
954	Polo-like kinase inhibitors in hematologic malignancies. 2016 , 98, 200-10	26
953	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. 2016 , 22, 61-70	29
952	Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. 2016 , 57, 609-15	19
951	Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. 2016 , 30, 261-7	20
950	The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. 2016 , 30, 789-99	101
949	Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia. 2016 , 30, 555-61	44
948	Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies. 2016 , 95, 115-124	8
947	Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. 2016 , 57, 1560-6	10
946	Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. 2016 , 30, 545-54	33
945	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. 2016 , 5, e1041701	29
944	Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. 2016 , 57, 812-9	7
943	Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age. 2016 , 30, 303-9	21
942	Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. 2016 , 67, 59-72	32
941	Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG. 2016 , 30, 229-37	18

940	NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. 2016 , 30, 473-83	44
939	Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. 2016 , 30, 55-64	23
938	Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. 2016 , 30, 484-91	154
937	Twist as a new prognostic marker in hematological malignancies. 2016 , 18, 113-24	18
936	Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia. 2016 , 30, 757-60	19
935	Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012. 2016 , 30, 24-31	59
934	Validation of 2 Prognostic Models in Hospitalized Patients With Advanced Hematological Malignancies in Japan. 2017 , 34, 258-262	7
933	Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. 2017 , 31, 26-33	48
932	Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia. 2017 , 58, 104-109	12
931	Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype. 2017 , 33, 49-55	2
930	Activity levels of natural anticoagulant proteins in childhood acute lymphoblastic leukemia: relation to thromboembolic complications and treatment. 2017 , 28, 1-7	3
929	Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience. 2017 , 58, 110-117	11
928	Feasibility of the AML profiler (SkylineArray) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach. 2017 , 35, 778-788	3
927	FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission. 2017 , 35, 392-394	
926	Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia. 2017 , 35, 789-796	14
925	Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis. 2017 , 56, 130-148	11
924	Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. 2017 , 31, 1217-1220	37
923	Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. 2017 , 147, 50-59	1

922	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. 2017 , 123, 2035-2042		11
921	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. <i>Blood</i> , 2017 , 129, 1636-1645	2.2	61
920	Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. 2017 , 96, 559-565		16
919	Frontline treatment of acute myeloid leukemia in adults. 2017 , 110, 20-34		68
918	Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study. 2017 , 96, 575-579		5
917	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. 2017 , 96, 469-478		4
916	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. 2017 , 52, 539-543		17
915	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 2017 , 52, 955-961		16
914	A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice. 2017 , 6, 349-360		35
913	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. 2017 , 102, 865-873		132
912	Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. 2017 , 31, 1306-1313		56
911	Precision oncology for acute myeloid leukemia using a knowledge bank approach. 2017 , 49, 332-340		155
910	Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group. 2017 , 31, 1012-1015		13
909	Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia. 2017 , 137, 15-16		
908	Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia. 2017 , 98, 443-449		5
907	Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. 2017 , 92, 388-396		17
906	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. 2017 , 58, 1-7		14
905	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. 2017 , 35, 1223-1230		27

904	lncRNA co-expression network model for the prognostic analysis of acute myeloid leukemia. 2017 , 39, 663-671		29
903	Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. 2017 , 35, 934-946		257
902	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. <i>Blood</i> , 2017 , 129, 2395-2407	2.2	116
901	Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia. 2017 , 102, 467-474		10
900	-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. 2017 , 102, 529-540		36
899	Treatment of Elderly Patients With Acute Myeloid Leukemia. 2017 , 18, 2		16
898	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. 2017 , 31, 185-192		42
897	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. <i>Blood</i> , 2017 , 129, 1333-1342	2.2	36
896	What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?. 2017 , 18, 3		6
895	Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. 2017 , 49, 25-33		14
894	Biology and relevance of human acute myeloid leukemia stem cells. <i>Blood</i> , 2017 , 129, 1577-1585	2.2	202
893	Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients. 2017 , 17, 312-319		14
892	Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. 2017 , 31, 2029-2036		36
891	Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia. 2017 , 10, 41		24
890	SNAP-Tag Technology: A Promising Tool for Ex Vivo Immunophenotyping. 2017 , 21, 315-326		1
889	Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. 2017 , 23, 3592-3600		6
888	Cytogenetic analysis of hematologic malignant diseases. 2017 , 499-575		1
887	Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry. 2017 , 98, 493-500		6

886	Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia. 2017 , 5, 369-374	1
885	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Mutations. 2017 , 7, 478-493	248
884	Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target. 2017 , 31, 2288-2302	14
883	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). 2017 , 10, 20	25
882	Predicting Chemotherapy Resistance in AML. 2017 , 12, 530-536	13
881	Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning. 2017 , 52, 932-935	10
880	Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia. 2017 , 58, 2558-2564	5
879	High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FLT3-ITD-/NPM1+ patients. 2017 , 58, 31-38	14
878	The Future of Targeting FLT3 Activation in AML. 2017 , 12, 153-167	32
877	MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells. 2017 , 108, 685-695	15
876	Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML. 2017 , 23, 4805-4816	18
875	Innovative strategies for adverse karyotype acute myeloid leukemia. 2017 , 24, 89-98	2
874	Allogeneic transplantation in primary refractory AML. 2017 , 52, 950-951	2
873	TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients. 2017 , 23, 941-948	7
872	A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia. 2017 , 56, 632-638	
871	Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. 2017 , 23, 1515-1522	14
870	Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. 2017 , 102, 1511-1518	25
869	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17. 2017 , 23, 1398-1404	8

868	Gingival enlargement in a pregnant woman with acute monocytic leukaemia: a case report. 2017 , 62, 386-389	2
867	Utilization Management in the Clinical Laboratory and Other Ancillary Services. 2017 ,	1
866	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. 2017 , 58, 1880-1886	9
865	Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia. 2017 , 105, 453-464	13
864	Therapy of older persons with acute myeloid leukaemia. 2017 , 60, 1-10	9
863	Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia. 2017 , 6, 384-388	3
862	Importance of CD117 in the Assignment of a Myeloid Lineage in Acute Leukemias. 2017 , 48, 212-215	0
861	Emerging cell cycle inhibitors for acute myeloid leukemia. 2017 , 22, 137-148	8
860	Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia. 2017 , 106, 411-417	1
859	Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial. 2017 , 23, 1491-1497	8
858	Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib. 2017 , 58, 2969-2972	11
857	Acute myeloid leukemia. 2017 , 89-96	
856	Overexpression of the giant FAT1 cadherin gene and its prognostic significance in de novo acute leukaemia patients. 2017 , 26, 505-512	
855	FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients. 2017 , 17, 767-773	11
854	ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML. 2017 , 99, 269-274	5
853	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. 2017 , 377, 454-464	1067
852	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. 2017 , 6, e1307491	24
851	Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation. 2017 , 52, 1047-1048	5

850	The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. 2017 , 31, 663-680		26
849	Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. 2017 , 8, 1573-1586		54
848	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. 2017 , 31, 2552-2559		13
847	Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. 2017 , 7, e564		30
846	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. 2017 , 59, 55-64		15
845	Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia. 2017 , 102, 1567-1577		24
844	Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. 2017 , 8, 185-195		6
843	Symptom Management and Psychosocial Needs of Adults With Acute Myeloid Leukemia During Induction Treatment: A Pilot Study. 2017 , 40, E31-E38		14
842	Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia. 2017 , 16, 281-287		1
841	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. <i>Blood</i> , 2017 , 130, 732-741	2.2	230
840	Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine. 2017 , 58, 2565-2572		6
839	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. 2017 , 92, 653-659		10
838	Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor. 2017 , 6, 357-364		14
837	Inclusion and response criteria for clinical trials in relapsed/refractory acute lymphoblastic leukemia and usefulness of historical control trials. 2017 , 102, e118-e119		1
836	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. 2017 , 123, 3050-3060		39
835	Clinical Relevance of RUNX1 and CFBF Alterations in Acute Myeloid Leukemia and Other Hematological Disorders. 2017 , 962, 175-199		6
834	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. 2017 , 96, 895-904		4
833	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. <i>Blood</i> , 2017 , 129, 2882-2895	2.2	49

832	Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles. 2017 , 16, 1031-1040		19
831	Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. 2017 , 23, 1064-1071		83
830	Clinical significance of isolated del(7p) in myeloid neoplasms. 2017 , 55, 18-22		3
829	Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia. 2017 , 177, 328-330		4
828	Rethinking the role of osteopontin in human acute myeloid leukemia. 2017 , 58, 1494-1497		6
827	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 424-447	2.2	2764
826	Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. 2017 , 92, 232-237		7
825	Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?. 2017 , 96, 363-371		7
824	Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). 2017 , 127, 72-86		14
823	Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia. 2017 , 102, e129-e131		15
822	Tetraploidy/near-tetraploidy acute myeloid leukemia. 2017 , 53, 20-27		8
821	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. 2017 , 23, 69-78		133
820	Significance of OCT1 Expression in Acute Myeloid Leukemia. 2017 , 23, 665-671		3
819	Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. 2017 , 92, 344-350		9
818	Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey. 2017 , 53, 74-81		23
817	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. 2017 , 102, 110-117		38
816	Hyperleukocytosis and leukostasis: management of a medical emergency. 2017 , 10, 147-154		30
815	MN1 and PTEN gene expression in acute myeloid leukemia. 2017 , 18, 177-182		8

814	CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. 2017 , 53, 39-49	16
813	Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. 2017 , 36, 3263-3273	7
812	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. 2017 , 102, 184-191	35
811	Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies. 2017 , 28, 231-241	16
810	Acute Leukemia. 2017 , 31, 1011-1028	18
809	Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. 2017 , 61, 108-116	25
808	Methods of Detection of Measurable Residual Disease in AML. 2017 , 12, 557-567	22
807	Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). 2017 , 96, 1993-2003	79
806	Standardy diagnostyki oraz nowe trendy w leczeniu ostrej białaczki szpikowej. 2017 , 48, 291-299	
805	Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. 2017 , 62, 51-55	5
804	Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. 2017 , 62, 84-90	5
803	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. 2017 , 99, 544-552	4
802	Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. 2017 , 7, 9509	16
801	Genetic, Hematologic and Psychological Aspects of Leukemia. 2017 , 667-755	1
800	The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia. 2017 , 12, 547-556	14
799	Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. 2017 , 19, 1336-1347	106
798	Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. 2017 , 62, 77-83	13
797	A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. 2017 , 7, 12892	23

796	Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. 2017 , 102, 2134-2140	20
795	Sub-clonal analysis of the murine C1498 acute myeloid leukaemia cell line reveals genomic and immunogenic diversity. 2017 , 192, 27-34	1
794	High Expression of AHSP, EPB42, GYPC and HEMGN Predicts Favorable Prognosis in FLT3-ITD-Negative Acute Myeloid Leukemia. 2017 , 42, 1973-1984	13
793	Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. 2017 , 61, 10-17	12
792	Targeting apoptosis in acute myeloid leukaemia. 2017 , 117, 1089-1098	42
791	Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34 Acute Myeloid Leukemia. 2017 , 26, 1460-1467	9
790	Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. 2017 , 61, 62-67	20
789	Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. 2017 , 92, 1318-1323	17
788	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. 2017 , 3, 1675-1682	78
787	Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1. 2017 , 60, 7984-7999	30
786	Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature. 2017 , 7, 11148	9
785	Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. 2017 , 61, 25-32	12
784	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. 2017 , 66, 1473-1484	32
783	Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia. 2017 , 142, 163-178	44
782	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. 2017 , 123, 4430-4439	30
781	Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia. 2017 , 56, 800-809	19
780	Successful haploidentical stem cell transplantation with prophylactic administration of liposomal amphotericin B after invasive pulmonary zygomycosis. 2017 , 18, 1-4	1
779	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. 2017 , 23, 6478-6486	21

778	The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. 2017 , 55, 76-85.e3	3
777	Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience. 2017 , 60, 109-114	14
776	JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). 2017 , 106, 310-325	10
775	Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. 2017 , 114, E7554-E7563	58
774	CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?. 2017 , 10, 853-862	19
773	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations. 2017 , 39, 379-384	1
772	Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia. 2017 , 99, 392-398	6
771	Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. 2020 , 95, 1304-1313	1
770	Inhibition of NF- κ B Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics. 2020 , 9,	1
769	The prognostic impact of abnormally expressed, long noncoding RNAs in acute myeloid leukemia: a meta-analysis. 2020 , 25, 219-228	1
768	After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia. 2020 , 2020, 2134647	1
767	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. 2020 , 21,	2
766	Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. 2020 , 9,	13
765	Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors. 2020 , 25,	1
764	The role of mitochondrial proteases in leukemic cells and leukemic stem cells. 2020 , 9, 1481-1487	4
763	Systematic Analysis of Autophagy-Related Signature Uncovers Prognostic Predictor for Acute Myeloid Leukemia. 2020 , 39, 1595-1605	10
762	Chemometric and Transcriptomic Profiling, Microtubule Disruption and Cell Death Induction by Secalonic Acid in Tumor Cells. 2020 , 25,	3
761	Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. 2020 , 27, 81	18

760	Management of Acute Myeloid Leukemia (AML) in Older Patients. 2020 , 22, 103	3
759	Long Noncoding RNA Maternally Expressed Gene 3 Is Downregulated, and Its Insufficiency Correlates With Poor-Risk Stratification, Worse Treatment Response, as Well as Unfavorable Survival Data in Patients With Acute Myeloid Leukemia. 2020 , 19, 1533033820945815	4
758	HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation. 2020 , 12,	3
757	Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse. 2021 , 106, 2325-2333	4
756	Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. 2020 , 26, 2098-2104	3
755	Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. 2020 , 86, 325-337	2
754	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. 2020 , 34, 2903-2913	18
753	Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients. 2020 , 10, 12761	9
752	Myeloproliferative Disorder with Intraoral Lesions in an Olive Baboon (<i>Papio anubis</i>). 2020 , 49, 337-340	
751	Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. 2020 , 26, 1995-2000	0
750	Impact of <i>Clostridioides difficile</i> infection on the outcome of patients receiving a hematopoietic stem cell transplantation. 2020 , 99, 428-436	2
749	Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action. 2020 , 59, 1521-1550	3
748	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. 2020 , 26, e322-e327	19
747	Morphologic remission status is limited compared to \bar{N} flow cytometry: a Children's Oncology Group AAML0531 report. 2020 , 4, 5050-5061	7
746	Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. 2020 , 4, 5246-5256	21
745	Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. 2020 , 5, 429-438	1
744	Comprehensive Analysis of Prognostic Markers for Acute Myeloid Leukemia Based on Four Metabolic Genes. 2020 , 10, 578933	3
743	Identification of the hub genes and pathways involved in acute myeloid leukemia using bioinformatics analysis. 2020 , 99, e22047	0

742	Long Non-Coding RNA Taurine Upregulated Gene 1 Targets miR-185 to Regulate Cell Proliferation and Glycolysis in Acute Myeloid Leukemia Cells in vitro. 2020 , 13, 7887-7896	4
741	Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. 2020 , 38, 754-762	3
740	Characterization of FLT3-ITD acute myeloid leukemia: molecular profiling of leukemic precursor cells. 2020 , 10, 85	4
739	TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1. 2020 , 39, 158	3
738	Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of and Expression. 2020 , 26, 5852-5859	9
737	Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. 2020 , 4, 3864-3874	15
736	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. 2020 , 4, 6064-6076	7
735	Antileukemic activity of sulfoxide nutraceutical allicin against THP-1 cells is associated with premature phosphatidylserine exposure in human erythrocytes. 2020 , 27, 3376-3384	6
734	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. 2020 , 10, 599933	4
733	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. 2020 , 4, 5735-5744	5
732	Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category. 2020 , 12,	1
731	SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. 2020 , 11, 956	7
730	High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. 2020 , 105, e507	5
729	CD34CD38CD123 Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. 2020 , 12,	4
728	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. 2020 , 4, 1942-1949	14
727	Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity. 2020 , 9,	11
726	Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study. 2020 , 12, e2020020	4
725	Cyclodextrin complexation studies as the first step for repurposing of chlorpromazine. 2020 , 584, 119391	10

724	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged . 2020 , 34, 3215-3227	24
723	Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia. 2020 , 117, 13670-13679	10
722	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. 2020 , 4, 2339-2350	7
721	Validation of the Functional Assessment of Cancer Therapy-Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy. 2020 , 126, 3542-3551	4
720	New translocation in acute myeloid leukemia M4 eos. 2020 , 14, 100209	0
719	miR-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells. 2020 , 44, 2021-2030	5
718	Novel Treatment Paradigms in Acute Myeloid Leukemia. 2020 , 108, 506-514	5
717	WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML). 2020 , 43, 204-215	8
716	Diagnostic and Therapeutic Considerations for Extramedullary Leukemia. 2020 , 22, 75	8
715	Effect and safety of gemtuzumab ozogamicin for the treatment of patients with acute myeloid leukaemia: a systematic review protocol. 2020 , 10, e032503	
714	Acute Myeloid Leukemia in Qatar (2010-2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes. 2020 , 11, 553	2
713	Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. 2020 , 38, 263-278.e6	22
712	Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. 2020 , 117, 15182-15192	37
711	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. 2020 , 95, 106385	14
710	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. 2020 , 190, e169-e173	4
709	Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia. 2020 , 19, 1875-1888	13
708	Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia. 2020 , 10, 685	12
707	RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia. 2020 , 26, 3597-3607	15

706	Development and validation of a 10-gene prognostic signature for acute myeloid leukaemia. 2020 , 24, 4510-4523	8
705	Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial. 2020 , 9, e1117	11
704	Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. 2020 , 61, 1688-1694	1
703	Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis. 2020 , 9, 3	3
702	Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia. 2020 , 12,	12
701	Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia. 2020 , 10, 327	6
700	Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. 2020 , 17, 994-1004	10
699	Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance. 2020 , 19, 57	32
698	Functional Classification of Mutations in Acute Myeloid Leukemia. 2020 , 12,	20
697	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine + idasanutlin in relapsed or refractory acute myeloid leukemia. 2020 , 16, 807-815	26
696	Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. 2020 , 189, 718-730	6
695	A Remarkable Remission: Treating HMA Refractory Transforming MDS with Single-Agent Low-Dose Cytarabine Leading to an Ongoing Six-Year OS. 2020 , 2020, 1540370	1
694	THBS1 Is a Novel Serum Prognostic Factors of Acute Myeloid Leukemia. 2019 , 9, 1567	12
693	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. 2020 , 34, 3149-3160	19
692	The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. 2020 , 13, 100780	
691	Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo. 2020 , 14, 2413-2422	6
690	Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid Leukemia Patients. 2020 , 12,	7
689	Driver Mutations in Acute Myeloid Leukemia with Inversion of Chromosome 16. 2020 , 54, 341-348	2

688	A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. 2020 , 98, 1069-1091	33
687	A rare case of acute myeloid leukemia with t(12;19)(q13;q13). 2020 , 14, 100216	1
686	Genome-wide DNA methylome analysis reveals methylation subtypes with different clinical outcomes for acute myeloid leukemia patients. 2020 , 9, 6296-6305	2
685	Assessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?. 2020 , 37, 259-268	0
684	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. 2020 , 126, 2183-2192	8
683	Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. 2020 , 61, 1188-1194	5
682	FOX11 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. 2020 , 11, 928	19
681	Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia. 2020 , 11, 2040620719899818	15
680	Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. 2020 , 38, 1430-1441	3
679	Somatostatin receptor mediated targeting of acute myeloid leukemia by photodynamic metal complexes for light induced apoptosis. 2020 , 10, 371	8
678	Identification of CD318 (CDCP1) as novel prognostic marker in AML. 2020 , 99, 477-486	8
677	Bone Marrow Clonogenic Myeloid Progenitors from -Mutated AML Patients Do Not Harbor the Mutation: Implication for the Cell-Of-Origin of AML. 2020 , 11,	1
676	Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. 2020 , 17, 1-10	9
675	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. 2020 , 34, 1577-1587	10
674	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. 2020 , 16, e464-e475	4
673	Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. 2020 , 21, 543-555	5
672	Hematopathology. 2020 , 1729-2141	
671	Anti-leukemia activities of selenium nanoparticles embedded in nanotube consisted of triple-helix β -d-glucan. 2020 , 240, 116329	17

670	Dimethylation of eEF1A at Lysine 55 Plays a Key Role in the Regulation of eEF1A2 on Malignant Cell Functions of Acute Myeloid Leukemia. 2020 , 19, 1533033820914295	5
669	Reducing the red blood cell transfusion threshold from 80 g/dl to 70 g/dl in acute myeloid leukaemia patients undergoing induction chemotherapy reduces transfusion rates without adversely affecting patient outcome. 2020 , 115, 570-578	4
668	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. 2020 , 95, 749-758	8
667	CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation. 2020 , 112, 57-64	3
666	Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. 2020 , 34, 3161-3172	57
665	Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. 2020 , 13, 489-499	6
664	Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia. 2020 , 12, 475-484	3
663	Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. 2020 , 99, 1845-1853	4
662	The first case of acute myeloid leukaemia/myeloid sarcoma with cytokeratin expression on blasts diagnosed on urine specimen. 2021 , 14, 343-347	0
661	Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment. 2020 , 37, 2288-2302	
660	Down-regulation of lncRNA NEAT1 regulated by miR-194-5p/DNMT3A facilitates acute myeloid leukemia. 2020 , 82, 102417	12
659	Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma. 2020 , 13, 207-211	3
658	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. 2020 , 4, 301-311	6
657	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. 2020 , 4, 611-616	10
656	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. 2020 , 4, 599-606	2
655	Disulfiram/cytarabine eradicates a subset of acute myeloid leukemia stem cells with high aldehyde dehydrogenase expression. 2020 , 92, 106351	7
654	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. 2021 , 35, 62-74	34
653	Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis. 2021 , 15, 1203-1216	13

652	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranlycypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. 2021 , 35, 701-711		21
651	Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia. 2021 , 192, 494-503		3
650	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. 2021 , 35, 712-723		4
649	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. 2021 , 144, 74-81		1
648	Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia. 2021 , 106, 574-579		1
647	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. 2021 , 35, 724-736		3
646	An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia. 2021 , 96, E17-E20		0
645	A systematic review finds Core Outcome Set uptake varies widely across different areas of health. 2021 , 129, 114-123		16
644	FLT3 ligand in acute myeloid leukemia: a simple test with deep implications. 2021 , 62, 264-270		2
643	WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience. 2021 , 21, e145-e151		2
642	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study?. 2021 , 100, 106489		11
641	miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2. 2021 , 25, 575-585		15
640	Cytogenetic and molecular genetic methods for chromosomal translocations detection with reference to the gene. 2021 , 58, 180-206		1
639	Clinical outcome of older adults with acute myeloid Leukemia: An analysis of a large tertiary referral Center over two decades. 2021 , 12, 540-549		0
638	Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells. <i>Blood</i> , 2021 , 137, 1694-1697	2.2	7
637	CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy. <i>Blood</i> , 2021 , 137, 2171-2181	2.2	9
636	Evaluation of the human type 3 adenoviral dodecahedron as a vector to target acute myeloid leukemia. 2021 , 20, 181-190		1
635	Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia. 2021 , 39, 121-131		2

634	Expression of ERV3-1 in leukocytes of acute myelogenous leukemia patients. 2021 , 773, 145363		3
633	FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias. 2021 , 52, 217-223		2
632	Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. 2021 , 47, 100773		18
631	Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL). 2021 , 12, 550-556		6
630	Research advances in nanomedicine, immunotherapy, and combination therapy for leukemia. 2021 , 109, 425-436		4
629	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. <i>Blood</i> , 2021 , 137, 524-532	2.2	7
628	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. 2021 , 113, 92-99		7
627	Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. 2021 , 62, 158-166		5
626	Chemotherapy and Pharmacology for Leukemia in Pregnancy. 2021 ,		
625	Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. 2021 , 100, 799-808		1
624	Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials. 2021 , 12, 21-32		1
623	Diagnosis and Classification of AML: WHO 2016. 2021 , 23-54		0
622	A clinical prediction model identifies a subgroup with inferior survival within intermediate risk acute myeloid leukemia. 2021 , 12, 4912-4923		1
621	Association of kinesin family member 2A with increased disease risk, deteriorative clinical characteristics, and shorter survival profiles in acute myeloid leukemia. 2020 , 54, e9173		3
620	Results of a pharmacoeconomic analysis of the rationality of the use of acute myeloid leukemia chemotherapy regimens with the use of various doses of cytarabine. 2021 , 30, 03003		
619	Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. 2021 , 100, 505-516		2
618	Gynecological Myeloid Sarcoma: Literature Review and a Case Report. 2021 , 14, 31-44		
617	Efficacy, Safety, and Tolerance of Gemtuzumab Ozogamicin Combined with FLAG/FLAG-Ida or Azacitidine in Relapsed/Refractory Acute Myeloblastic Leukemia. 2021 , 14, 299-307		

616	Expression profiles of HMGB1 on B-CLL related leukocytes contribute to prediction of relapse. 2021 , 226, 152048	0
615	Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia. 2021 , 26, 371-379	1
614	Prognostic Factors in AML. 2021 , 127-175	1
613	Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia. 2021 , 62, 1450-1457	2
612	HSCT in Malignancies. 2021 , 99-114	
611	Studying leukemia stem cell properties and vulnerabilities with human iPSCs. 2020 , 50, 102117	1
610	Clinical Manifestation and Diagnostic Workup. 2021 , 119-126	
609	Dual Kinase Targeting in Leukemia. 2021 , 13,	1
608	Characteristics and transplant outcome of myeloid sarcoma: a single-institute study. 2021 , 113, 682-692	5
607	Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia. 2021 , 13,	2
606	Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia. 2021 , 26, 111-122	1
605	Prognostic factors in elderly patients with acute myeloid leukemia. 2021 , 2, 66-74	
604	A narrative review of central nervous system involvement in acute leukemias. 2021 , 9, 68	8
603	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. 2021 , 13,	2
602	CAR-T Therapy, the End of a Chapter or the Beginning of a New One?. 2021 , 13,	2
601	A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. 2021 , 127, 2003-2014	5
600	Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation. 2021 , 147, 2659-2670	0
599	Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. 2021 , 27, 3141-3153	12

598	Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. 2021 , 10, 7		0
597	Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. 2021 , 192, e148-e151		2
596	Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients. 2021 , 2, 100202		2
595	Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure. 2021 , 13,		5
594	DNA methylation analysis improves the prognostication of acute myeloid leukemia. 2021 , 2, 211-218		1
593	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. 2021 , 31, 747-761		4
592	Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome. 2021 , 62, 1907-1919		
591	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. 2021 , 100, 1181-1194		8
590	The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia. 2021 , 56, 1257-1265		4
589	ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. 2021 , 27, 256.e1-256.e7		2
588	Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. <i>Blood</i> , 2021 , 137, 3641-3655	2.2	5
587	Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling. 2021 , 11, 657191		4
586	Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy. 2021 , 100, 1159-1167		1
585	Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients.		
584	Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. 2021 , 27, 2848-2860		5
583	Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. 2021 , 16, e0249087		1
582	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. 2021 , 106, 724-733		0
581	Reinduction chemotherapy regimen involved decitabine and cladribine improves the prognosis of patients with relapsed or refractory acute myeloid leukemia: A preliminary study. 2021 , 149, 901		

580	LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBP β . 2021 , 5, 2305-2318			3
579	Update on drug transporter proteins in acute myeloid leukemia: Pathological implication and clinical setting. 2021 , 160, 103281			3
578	Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance. 2021 , 9,			0
577	High expression of ISG20 predicts a poor prognosis in acute myeloid leukemia. 2021 , 31, 255-261			
576	Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. 2021 , 107, 111-121			2
575	Tumor suppressors in acute myeloid leukemia. 2021 , 62, 2320-2330			2
574	High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia. 2021 , 21, 475			5
573	[68/f-Progressive dyspnea on exertion and petechiae : Preparation for the medical specialist examination: part 43]. 2021 , 62, 304-308			
572	Mitochondrial metabolism as a target for acute myeloid leukemia treatment. 2021 , 9, 17			10
571	An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. 2021 , 14, 407-417			
570	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with -mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. 2021 , 106, 2986-2989			1
569	A slow-go prognosis for older patients with newly diagnosed AML. <i>Blood</i> , 2021 , 138, 501-502	2.2		0
568	FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation. 2021 , 15, 2300-2317			0
567	A graphical, interactive and GPU-enabled workflow to process long-read sequencing data.			
566	Cancer Prognosis According to Parthanatos Features.			
565	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. 2021 , 21, 338-344			4
564	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. 2021 , 11, 10017			0
563	Expression Levels of Il-6 and Il-18 in Acute Myeloid Leukemia and Its Relation with Response to Therapy and Acute GvHD After Bone Marrow Transplantation. 2021 , 12, 465-471			0

562	What can Heraclitus tell us about AML?. <i>Blood</i> , 2021 , 137, 2719-2720	2.2
561	Anti-Tumor Effects of in Acute Myeloid Leukemia. 2021 , 11, 694594	0
560	Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. 2021 , 20, 1702-1712	3
559	Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. 2021 , 15, 2285-2299	0
558	RNA modifications in hematopoietic malignancies: a new research frontier. <i>Blood</i> , 2021 , 138, 637-648	2.2 3
557	Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. 2021 , 12, 683381	1
556	Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia. 2021 , 142, 155508	1
555	KLOFARABİN BAZLI TEDAVİ ALAN RELAPS VEYA REFRAKTER AKUT LİSEMİYANILI HASTALARIN RETROSPEKTİF DEĞERLENDİRİLMESİ	
554	DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia. 2021 , 11, 12148	3
553	Ketorolac-fluconazole: A New Combination Reverting Resistance in from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study. 2021 , 12, 465-474	1
552	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. 2021 , 24, 102651	0
551	Efficacy and Safety of Homoharringtonine for the Treatment of Acute Myeloid Leukemia: A Meta-analysis. 2021 , 21, e752-e767	1
550	Transcript-Level Dysregulation of Family Genes in Acute Myeloblastic Leukemia. 2021 , 13,	3
549	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. 2021 , 62, 2727-2736	
548	Fusion gene detection by RNA sequencing complements diagnostics of acute myeloid leukemia and identifies recurring NRIP1-MIR99AHG rearrangements. 2021 ,	3
547	Macrophages in Acute Myeloid Leukaemia: Significant Players in Therapy Resistance and Patient Outcomes. 2021 , 9, 692800	3
546	Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. 2021 , 39, 3261-3272	1
545	Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome. 2021 , 9, e04287	0

544	Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. 2021 , 10, 39	8
543	Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation. 2021 , 7, 1220-1232 ¹	
542	Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy-Is it prognostic?-a single-center retrospective study. 2021 , 11, 128	1
541	Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG). 2021 , 21, e635-e643	
540	Curcumin attenuates Adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR/miR-20a-5p/WT1 axis. 2021 , 101, 1308-1317	4
539	Silencing of circTASP1 inhibits proliferation and induces apoptosis of acute myeloid leukaemia cells through modulating miR-515-5p/HMGA2 axis. 2021 , 25, 7367-7380	2
538	Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. 2021 , 14, 107	2
537	Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy. 2021 , 100, 2603-2611	
536	Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment. 2021 , 35, 101564	2
535	Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. 2021 , 100, 2387-2398	1
534	Utility of Palliative Prognostic Index in Predicting Survival Outcomes in Patients With Hematological Malignancies in the Acute Ward Setting. 2021 , 10499091211028820	2
533	Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?. 2021 , 23, 109	0
532	Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients. 2021 , 21, e960-e969	1
531	The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. 2021 , 48, 100806	0
530	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. 2021 , 62, 3192-3203	1
529	Eukaryotic initiation factor-2, gamma subunit, suppresses proliferation and regulates the cell cycle via the MAPK/ERK signaling pathway in acute myeloid leukemia. 2021 , 147, 3157-3168	0
528	A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia. 2021 , 11, 702239	1
527	Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. 2021 , 256-257, 68-76	0

526	The Prevalence and Prognostic Impacts of Nucleophosmin Mutations in Adult Patients with De Novo Acute Myeloid Leukemia. 2021 , 9, 632-638	
525	A graphical, interactive and GPU-enabled workflow to process long-read sequencing data. 2021 , 22, 626	0
524	Serum estrogen and its soluble receptor levels in Egyptian patients with acute leukemia: case-control study. 2021 , 22,	0
523	Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. 2021 , 39, 2535-2538	3
522	Deubiquitinases in hematological malignancies. 2021 , 9, 66	3
521	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. 2021 , 5, e617	1
520	Clinical features and outcome of <i>Aeromonas sobria</i> bacteremia in pediatric and adult patients with hematologic malignancies: A single-center retrospective study in Peru. 2021 , 16, e0255910	0
519	High expression of long noncoding RNA NORAD is associated with poor clinical outcomes in non-M3 acute myeloid leukemia patients. 2021 ,	0
518	Magic and mystery of microRNA-32. 2021 , 25, 8588-8601	3
517	DDX41 is needed for pre-and post-natal hematopoietic stem cell differentiation in mice.	
516	Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia. 2021 , 385, 834-843	
515	Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia. 2021 , 7, 1354-1354	
514	Consolidation in AML: Abundant opinion and much unknown. 2021 , 51, 100873	0
513	NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both and. 2021 , 20, 2218-2227	0
512	The role of tumor necrosis factor receptor superfamily member 4 (TNFRSF4) gene expression in diagnosis and prognosis of acute myeloid leukemia. 2021 , 48, 6831-6843	0
511	Co-Treatments of Edible Curcumin from Turmeric Rhizomes and Chemotherapeutic Drugs on Cytotoxicity and FLT3 Protein Expression in Leukemic Stem Cells. 2021 , 26,	1
510	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. 2021 , 56, 3068-3077	3
509	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. 2021 , 2, 616-629	8

- 508 Rational biomarker development for the early and minimally invasive monitoring of AML. **2021**, 5, 4515-4520 1
- 507 Construction of a solid Cox model for AML patients based on multiomics bioinformatic analysis.
- 506 Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. **2021**, 56, 2975-2980 0
- 505 In-depth time-dependent analysis of the benefit of Allo-HSCT for elderly patients with CR1 AML: a FILO study. **2021**, 0
- 504 Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System. **2021**, 11, 0
- 503 DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis. **2021**, 11, 18012
- 502 Mismatch in SIRP β , a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. **2021**, 5, 3407-3417 0
- 501 MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations. **2021**, 1 1
- 500 A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia. **2021**, 11, 726926 0
- 499 Platelet transcriptome profiles provide potential therapeutic targets for elderly acute myelocytic leukemia patients. **2021**, 19, 388 0
- 498 The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors. **2021**, 12, 5397 0
- 497 Systematic Construction and Validation of an RNA-Binding Protein-Associated Prognostic Model for Acute Myeloid Leukemia. **2021**, 12, 715840 1
- 496 In Silico Methods for the Identification of Diagnostic and Favorable Prognostic Markers in Acute Myeloid Leukemia. **2021**, 22, 3
- 495 Prognosis and Outcome of Fit Patients with Acute Myeloid Leukemia in Kuwait. **2021**, 21, e736-e743 0
- 494 Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. **2021**, 27, 771.e1-771.e10 0
- 493 Adverse prognostic impact of complex karyotype (β cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). **2021**, 109, 106612 3
- 492 Identification of biomarkers for acute leukemia via machine learning-based stemness index. **2021**, 804, 145903 1
- 491 Importance of targeted therapies in acute myeloid leukemia. **2021**, 107-133 0

490	AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. 2021 , 39, 1139-1149	2
489	The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study. 2020 , 9, 2403-2413	5
488	225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. 2021 , 10, 1128-1140	9
487	Fluorescent In Situ Hybridization in Suspension by Imaging Flow Cytometry. 2016 , 1389, 111-26	7
486	Acute Myeloid Leukemia in Adults. 2019 , 507-521	3
485	The role of inflammation in leukaemia. 2014 , 816, 335-60	14
484	Leukostasis, Infiltration and Pulmonary Lysis Syndrome Are the Three Patterns of Leukemic Pulmonary Infiltrates. 2011 , 509-520	1
483	Leukämien und Lymphome. 2018 , 267-357	1
482	The constitutive protease release by primary human acute myeloid leukemia cells. 2017 , 143, 1985-1998	11
481	Current concepts and future directions for hemato-oncologic diagnostics. 2020 , 151, 102977	6
480	Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. 2018 , 8, 52	34
479	High expression of AK1 predicts inferior prognosis in acute myeloid leukemia patients undergoing chemotherapy. 2020 , 40,	3
478	The M2 macrophage marker : a novel prognostic indicator for acute myeloid leukemia. 2020 , 9, 1683347	36
477	Recommendations for Reporting on Rehabilitation Interventions. 2021 , 100, 5-16	8
476	Sex disparity in acute myeloid leukemia Evidence from a study of FLT3-ITD mutated patients.	1
475	Diagnostic value of blood gene expression-based classifiers as exemplified for acute myeloid leukemia.	1
474	Optimal control of acute myeloid leukaemia.	1
473	Spectral model for diagnosis of acute leukemias in whole blood and plasma through Raman spectroscopy. 2018 , 23, 1-11	3

472	ImmunoPET, [Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model. 2019 , 25, 7463-7474	8
471	The intersection of genetic and chemical genomic screens identifies GSK-3 β as a target in human acute myeloid leukemia. 2012 , 122, 935-47	84
470	CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR δ signaling. 2013 , 123, 299-314	38
469	Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. 2014 , 124, 222-36	52
468	Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for prime time? 2014 , 2014, 222-233	4
467	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. 2016 , 2016, 24-32	16
466	Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. <i>Blood</i> , 2020 , 136, 224-234	2.2 19
465	Haploidentical, Unmanipulated Granulocyte Colony-Stimulating Factor (G-CSF)-Primed Peripheral Blood Stem Cell Transplants for Acute Myeloid Leukemia (AML) in Remission: A Single Center Experience. 2019 , 24, 367-373	1
464	Outcome and Prognostic Factors of High-Risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. 2019 , 24, 328-340	4
463	High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. 2018 , 24, 758-767	11
462	A 10-Long Non-Coding RNA-Based Expression Signature as a Potential Biomarker for Prognosis of Acute Myeloid Leukemia. 2019 , 25, 4999-5004	7
461	Advances in treating acute myeloid leukemia. 2014 , 6, 96	25
460	Effect of <i>Orostachys japonicus</i> on Apoptosis and Autophagy in Human monocytic leukemia Cell line THP-1 via Inhibition of NF- κ B and Phosphorylation of p38 MAPK. 2019 , 40, 35-50	0
459	A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. 2016 , 12, e1004890	21
458	Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). 2010 , 5, e13543	25
457	Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats. 2012 , 7, e33213	50
456	β -Tomatine-mediated anti-cancer activity in vitro and in vivo through cell cycle- and caspase-independent pathways. 2012 , 7, e44093	24
455	Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study. 2012 , 7, e52695	21

454	Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. 2013 , 8, e60699	19
453	The role of therapeutic leukapheresis in hyperleukocytotic AML. 2014 , 9, e95062	46
452	The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. 2014 , 9, e112619	8
451	Gene expression profiles associated with pediatric relapsed AML. 2015 , 10, e0121730	20
450	High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials. 2015 , 10, e0125612	16
449	Complementation of the Yeast Model System Reveals that <i>Caenorhabditis elegans</i> OCT-1 Is a Functional Transporter of Anthracyclines. 2015 , 10, e0133182	11
448	Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling. 2016 , 11, e0155226	5
447	Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. 2016 , 11, e0160871	7
446	A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. 2016 , 11, e0164499	7
445	Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital. 2011 , 66, 1335-40	5
444	[Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia]. 2016 , 88, 104-108	1
443	Long non-coding RNA RPPH1 promotes the proliferation, invasion and migration of human acute myeloid leukemia cells through down-regulating miR-330-5p expression. 2019 , 18, 824-837	8
442	Identification of prognostic genes in the acute myeloid leukemia microenvironment. 2019 , 11, 10557-10580	21
441	Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations. 2016 , 7, 54825-54837	17
440	Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. 2016 , 7, 49539-49551	10
439	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. 2016 , 7, 55083-55097	23
438	Targeting binding partners of the CBF-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia. 2016 , 7, 66255-66266	4
437	Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. 2016 , 7, 62377-62385	10

- 436 CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. **2013**, 4, 1438-48 18
- 435 Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. **2016**, 7, 85937-85947 9
- 434 Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. **2016**, 7, 86239-86256 14
- 433 Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF- κ B inhibition in acute myeloid leukemia (AML). **2017**, 8, 7946-7963 27
- 432 In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia. **2017**, 8, 6341-6352 10
- 431 Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome. **2017**, 8, 23073-23086 21
- 430 Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. **2014**, 5, 916-32 40
- 429 ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. **2017**, 8, 26129-26141 11
- 428 TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population. **2017**, 8, 18337-18347 20
- 427 Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. **2017**, 8, 26613-26624 13
- 426 NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. **2017**, 8, 49548-49563 23
- 425 Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. **2017**, 8, 67891-67903 2
- 424 Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia. **2017**, 8, 57948-57963 3
- 423 overexpression independent of mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. **2017**, 8, 66087-66097 18
- 422 Analysis of splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. **2017**, 8, 95163-95175 6
- 421 Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline. **2017**, 8, 88697-88707 9
- 420 is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair. **2017**, 8, 95038-95053 6
- 419 High copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. **2017**, 8, 87944-87954 14

418	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. 2018 , 9, 4961-4968	13
417	Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. 2018 , 9, 26724-26736	9
416	A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy. 2014 , 5, 12675-93	15
415	Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia. 2018 , 9, 30128-30145	22
414	Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. 2018 , 9, 32885-32899	12
413	Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. 2018 , 9, 36603-36612	5
412	Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. 2019 , 10, 1250-1265	10
411	High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia. 2015 , 6, 5299-309	18
410	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. 2015 , 6, 8388-96	52
409	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. 2011 , 2, 850-61	26
408	Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110 β subunit of PI3 kinase. 2015 , 6, 8062-70	12
407	TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia. 2015 , 6, 20977-92	27
406	Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis. 2015 , 6, 25109-20	43
405	The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. 2015 , 6, 31613-27	69
404	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. 2015 , 6, 31284-94	15
403	High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis. 2015 , 6, 33217-25	21
402	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. 2015 , 6, 42569-74	25
401	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. 2015 , 6, 38061-78	16

400	Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia. 2016 , 7, 2585-95	12
399	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. 2016 , 7, 7586-96	11
398	Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. 2016 , 7, 23239-50	9
397	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. 2016 , 7, 32532-42	58
396	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. 2016 , 7, 38974-38987	32
395	Intrinsic resistance to PIM kinase inhibition in AML through p38 β -mediated feedback activation of mTOR signaling. 2016 , 7, 37407-37419	14
394	Immune Checkpoint Inhibitors in AML-A New Frontier. 2020 , 20, 545-557	1
393	The Evolving AML Genomic Landscape: Therapeutic Implications. 2020 , 20, 532-544	3
392	Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients. 2020 , 20, 145-151	3
391	Core Data Elements in Acute Myeloid Leukemia: A Unified Medical Language System-Based Semantic Analysis and Experts' Review. 2019 , 7, e13554	5
390	Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis. 2018 , 19, 325-329	11
389	Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases. 2018 , 19, 421-425	4
388	A case of acute leukaemia in a 38-years old female. 2012 , 18, 83-85	2
387	Assessment of the Diagnostic Potential of miR-29a-3p and miR-92a-3p as Circulatory Biomarkers in Acute Myeloid Leukemia. 2019 , 20, 3625-3633	6
386	Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia. 2019 , 20, 1749-1755	4
385	IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics. 2020 , 21, 721-725	2
384	The treatment of elderly patients with acute myeloid leukemia. 2011 , 108, 863-70	38
383	The indications for allogeneic stem cell transplantation in myeloid malignancies. 2015 , 112, 262-70	9

382	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of -ITD in Mutated AML, Irrespectively of -ITD Allelic Burden. 2020 , 13,	3
381	Recent advances in the treatment of acute myeloid leukemia. 2010 , 2, 55	11
380	[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia]. 2016 , 37, 94-9	1
379	[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colony-stimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia]. 2016 , 37, 571-5	3
378	[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017)]. 2017 , 38, 177-182	8
377	An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity. 2020 ,	2
376	Antiproliferative effects of L-asparaginase in acute myeloid leukemia. 2020 , 20, 2070-2078	3
375	Long non-coding RNA ANRIL is a potential indicator of disease progression and poor prognosis in acute myeloid leukemia. 2021 , 23,	1
374	Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia. 2013 , 25, 389-96	5
373	Results of treatment of acute myeloid leukemia in central part of Iran. 2013 , 2, 51	6
372	Diagnostic & prognostic role of microRNAs in paediatric acute myeloid leukaemia. 2016 , 144, 807-814	1
371	Utility of transmission electron microscopy in small round cell tumors. 2015 , 49, 93-101	5
370	Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia. 2013 , 5, 196-204	5
369	Therapy-related myeloid neoplasms - what have we learned so far?. 2016 , 8, 231-42	12
368	Serum levels of soluble adhesion molecules in newly diagnosed acute myeloid leukemia and in complete remission suggest endothelial cell activation by myeloblasts. 2017 , 161, 92-99	2
367	Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission. 2011 , 33, 179-84	2
366	Current Cytogenetic Abnormalities in Acute Myeloid Leukemia.	0
365	Acute myeloid leukemia diagnosis in the 21st century. 2010 , 134, 1427-33	46

364	Use of Flow Cytometry in Clinical Practice. 2015 , 6, 435-40	9
363	Impact of Global and Gene-Specific DNA Methylation in de Novo or Relapsed Acute Myeloid Leukemia Patients Treated with Decitabine. 2016 , 17, 431-7	7
362	The 100 Most Cited Papers About Cancer Epigenetics. 2020 , 12, e7623	2
361	Comparative analysis of infectious complications with outpatient inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. 2021 , 1-10	0
360	Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted next-generation sequencing. 2021 , e1573	
359	A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. 2021 , 10,	3
358	Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.	
357	Advances in acute myeloid leukemia. 2021 , 375, n2026	16
356	Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014). 2021 ,	1
355	CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. 2021 , 11, 21230	2
354	Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. 2021 , 11, 20745	2
353	Treatment of Acute Myeloid Leukemia. 2011 , 121-160	1
352	Blood. 2011 , 549-577	
351	Hämatologische und onkologische Erkrankungen. 2011 , 607-718	
350	Cytogenetic analysis in acute myeloid leukaemia. 2011 , 730, 63-77	
349	Acute Myeloid Leukemia. 103-126	
348	Acute Myeloid Leukemia (AML). 2012 , 1-36	
347	Krankheiten des Blutes und der blutbildenden Organe. 2012 , 579-605	

346 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61

345 Mechanisms Linking Obesity and Leukemia Prognosis. **2012**, 47-69

1

344 Hematology. **2012**, 767-871

343 [Current treatment of acute myeloid leukaemia in adults]. **2012**, 153, 243-9

2

342 Pharmacogenomics in Acute Myeloid Leukemia. **2013**, 237-248

1

341 Lymphoma and Leukaemia. **2013**, 363-490

340 Outcome of second/third allogeneic hematopoietic stem cell transplantations for a relapse of acute leukemia after the first transplantation. **2013**, 16, 17-24

339 Blood. **2013**, 665-694

338 Blood malignancies in Mazandaran province of Iran. **2013**, 14, 1053-6

7

337 Chemical Genomic Approaches to Eradicate Leukemia Stem Cells. **2014**, 93-101

336 Akute myeloische Leukämie. **2014**, 1-13

335 WHO Classification of Hematologic Malignancies. **2014**, 219-225.e2

334 Molecular Testing in Hematologic Malignancies. **2014**, 135-167

333 Hematopoietic Stem Cell Transplantation. **2014**, 485-492.e2

332 Acute Leukemias in Adults. **2014**, 1890-1906

331 Encyclopedia of Cancer. **2014**, 1-7

330 Encyclopedia of Cancer. **2014**, 46-50

329 Genetic Mechanisms and Molecular Markers of Neoplastic Transformation in Acute Myeloid Leukemia. **2012**, 29-53

328 [Treatment of acute myeloid leukemia -- a single center experience (2007-2013)]. **2014**, 155, 653-8

327 The Cancer Cell-Kill Paradigm and Beyond. **2015**, 101-128

326 Acute Myeloid Leukemia. **2015**, 63-83

325 Indications for Hematopoietic Transplantation for AML. **2015**, 777-797

324 Akute Leukämien. **2015**, 1-9

323 Akute myeloische Leukämie (AML) im Kindesalter. **2015**, L11.1-L11.12

322 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

321 Case 95. 351-354

320 Comparison of the efficacy of chemotherapy and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first remission in adults. **2015**, 22, 66-80

319 Leukaemia. 427-448

318 Leucemia mieloide aguda simulando fiebre por virus Chikungunya.. **2016**, 7, 117-122

317 Akute Leukämien des Erwachsenen. **2016**, 119-133

316 Radionuclide Therapy of Leukemias and Multiple Myeloma. **2016**, 1-39

315 Acute Myeloid Leukemia. **2016**, 527-559

314 Therapeutic Leukapheresis for the Management of Hyperleukocytosis: Ten-year Experience in a Tertiary Care Hospital. **2016**, 6, 159

313 Blood. **2016**, 1-34

312 Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemias: Prognostic Significance of Complex Karyotype Including del(5q), \square , del(7q) Abnormalities. **2016**, 9, 271-278 1

311 Genetic Mutations in Acute Myeloid Leukemia. **2016**, 9, 245-256 1

- 310 High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: A prospective pilot study from India. **2016**, 143, S11-S16 5
- 309 Personally tailored cancer management based on knowledge banks of genomic and clinical data.
- 308 Leukemia. **2017**, 987-1005
- 307 Acute Myelogenous Leukemia. **2017**, 135-149
- 306 Utilization Management of Genetic Testing. **2017**, 219-233
- 305 Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemias with Hyperdiploid Karyotype. **2016**, 9, 383-390 1
- 304 Radionuclide Therapy of Leukemias and Multiple Myeloma. **2017**, 1157-1195
- 303 ETHNIC PECULIARITIES OF DISTRIBUTION OF ACUTE MYELOBLASTIC LEUKAEMIA IN CHILDRENS POPULATION IN KYRGYZSTAN. **2017**, 19, 497-500
- 302 Leukemieñ en myelodysplasie. **2017**, 587-600
- 301 Akute Leukñien. **2017**, 353-380
- 300 Akute myeloische Leukñie beim alten und geriatrischen Patienten. **2017**, 1-16
- 299 Leukaemia. 427-448
- 298 Preparation of Quality Control Slides and Establishment of an External Quality Assessment Program for Five Special Stains Routinely Used in Diagnostic Hematology. **2017**, 39, 1-8
- 297 Modified Intermediate-Dose Cytarabine Combined with Daunorubicin Induction and Re-Induction Protocol Use in Patients with Acute Myeloid Leukemia. **2017**, 10,
- 296 Cytogenetic and Molecular Genetic Prognostic Factors of Acute Myeloid Leukemia. **2017**, 10, 227-234
- 295 Acute Myeloid Leukemia with Recurrent Genetic Abnormalities, Part II: Mutations Involving CEBPA, NPM1, and RUNX1. **2018**, 27-46
- 294 Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic Leukemia. **2017**, 10, 485-493 2
- 293 Acute Myeloid Leukemia and Acute Respiratory Failure: Early Diagnosis and a Practical Approach. **2018**, 103-112

- 292 High-mobility group box 1 is a promising diagnostic and therapeutic monitoring biomarker in Cancers: A review. **2018**, 5, 183-241 2
- 291 Signaling Landscape of AML: The Story So Far. **2018**, 233-262
- 290 Akute myeloische Leukämie beim alten und geriatrischen Patienten. **2018**, 213-228
- 289 THE INCIDENCE OF LEUKAEMIA IN KYRGYZSTAN IN CHILDREN UNDER 5 YEARS. **2018**, 20, 69-72
- 288 Tyrosine Kinases, microRNAs, Epigenetics: New Insights in the Mechanisms of Leukemogenesis. **2018**, 11-25
- 287 Classes of ITD predict outcomes in patients with AML treated with FLT3 inhibitors.
- 286 Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodeling. 1
- 285 Stratified computational meta-analysis of 2213 acute myeloid leukemia patients reveals age- and sex-dependent gene expression signatures.
- 284 Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia. **2019**, 56, 167-172
- 283 Large Unstained Cell, Blast Suspect and Delta Neutrophil Index II Analyzed with Automated Hematology Analyzer as Parameters for the Prediction of Acute Leukemia Relapse. **2019**, 9, 126
- 282 FLIM Imaging of NAD(P)H to track metabolic changes of non-adherent leukemia cells using micro cell trapping arrays. **2019**, 1
- 281 FLIM imaging of auto-fluorescent NAD(P)H and FAD to track metabolic changes of non-adherent leukemia cells using microfluidic trapping array. **2019**,
- 280 Prognostic Value of Genetic Mutations in Patients with Acute Myeloid Leukemias: Results of a Cooperative Study of Hematology Clinics of Saint Petersburg (Russia) and Charite Clinic (Germany). **2019**, 12, 211-219 1
- 279 A case of myeloid sarcoma with initial symptoms in the oral cavity. **2019**, 65, 229-233
- 278 Role of FLT3 gene mutations in acute myeloid leukemia: effect on course of disease and results of therapy. **2019**, XIV, 1
- 277 AML ImmunoPET: ⁶⁴Cu-DOTA-anti-CD33 PET-CT imaging of AML in Xenograft mouse model.
- 276 Prediction of FLAG – Ida Regimen Efficacy in Patients with Relapsed/Refractory Acute Myeloid Leukemia. **2019**, 12, 289-296 1
- 275 The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia. **2020**, 37, 116-120 3

- 274 Proteome and phosphoproteome changes associated with prognosis in acute myeloid leukemia.
- 273 Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias. 1
- 272 Intracranial hemorrhage in newly diagnosed non-promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy. 2021, 1
- 271 Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. 2021, 2021,
- 270 BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies. 2021, 10, 1
- 269 HSCT in Malignancies. 2020, 1-16
- 268 Syndromes myélodysplasiques et leucémies aiguës. 2020, 270-278.e3
- 267 JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy. 2021, 22, 66-78 1
- 266 Insights into Acute Myeloid Leukemia: Critical Analysis on its Wide Aspects. 2020, 1-9 0
- 265 A very rare case of FLT3-D835 positive blastic plasmacytoid dendritic cell neoplasm. 2020, 7, 57-62
- 264 SALL4 Gene Expression in Acute Myeloid Leukemia. 2019, 20, 3121-3127 1
- 263 Acute Leukemia of Myeloid, Lymphoid, and Ambiguous Lineage and Related Malignancies. 2020, 383-533 1
- 262 CHAPTER 11:Immunological Detection Methods for Biomarkers. 2020, 223-252
- 261 Dendritic Cell-Regulated T Cell Immunity and Tolerance against Acute Myeloid Leukemia. 2020, 279-296
- 260 Hypomethylating Agents Use in Acute Myeloid Leukemia: A Single-Center Experience. 2020, 41, 202-208
- 259 Are the conventional risk factors still valid for acute myeloid leukemia patients?. 5-11
- 258 Integrated - and -Glycomics of Acute Myeloid Leukemia (AML) Cell Lines. 2021, 10, 1
- 257 IER3 (IEX-1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients. 2021,

256	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. 2021 ,	0
255	CD123-Targeted Nano-Curcumin Molecule Enhances Cytotoxic Efficacy in Leukemic Stem Cells. 2021 , 11,	1
254	Bayesian variable selection for high-dimensional data with an ordinal response: identifying genes associated with prognostic risk group in acute myeloid leukemia. 2021 , 22, 539	1
253	Chemotherapy Protocols for Leukemia During Pregnancy. 2021 , 49-75	
252	High-dimensional mass cytometry analysis of NK cell alterations in Acute Myeloid Leukemia identifies a subgroup with adverse clinical outcome.	
251	225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.	
250	Deciphering the role of Wnt signaling in acute myeloid leukemia prognosis: how alterations in DNA methylation come into play in patients' prognosis. 2020 , 146, 3097-3109	0
249	RNF5 Regulation of RBBP4 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors.	
248	Expression of ERV3-1 in Leukocytes of Acute Myelogenous Leukemia Patients.	
247	Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. 2012 , 2, 254-64	36
246	Gene mutations and molecularly targeted therapies in acute myeloid leukemia. 2013 , 3, 29-51	35
245	Acute myeloid leukemia with adverse cytogenetic risk. 2012 , 26, 714, 723	1
244	Granulocytic sarcoma: a systematic review. 2013 , 3, 265-70	83
243	To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. 2012 , 10, 655-62	
242	Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide. 2014 , 7, 4765-73	10
241	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. 2013 , 11, 571-7	27
240	Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. 2014 , 7, 6832-40	37
239	A Case Report: Acute Myeloid Leukemia (FAB M7). 2014 , 4, 188-90	6

238	FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION. 2015 , 77, 7-17	35
237	Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. 2016 , 13, 41-54	6
236	Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. 2016 , 13, 317-29	21
235	Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups. 2016 , 17, 5251-5256	4
234	Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia. 2017 , 18, 413-420	1
233	High Prevalence of Vitamin D Deficiency in Newly Diagnosed Acute Myeloid Leukemia Patients and Its Adverse Outcome. 2017 , 11, 209-216	4
232	Characteristics of De Novo Acute Myeloid Leukemia Patients in Palestine: Experience of An-Najah National University Hospital. 2017 , 18, 2459-2464	3
231	Acute Myeloid Leukemia as the Main Cause of Pancytopenia in Iranian Population. 2017 , 12, 265-271	
230	Association between TLR2 and TLR4 Expression and Response to Induction Therapy in Acute Myeloid Leukemia Patients. 2018 , 12, 303-312	9
229	MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4. 2019 , 11, 3384-3397	9
228	miR-126 promotes the growth and proliferation of leukemia stem cells by targeting DNA methyltransferase 1. 2018 , 11, 3454-3462	0
227	Bioinformatics and experimental studies of anti-leukemic activity from 6-gingerol demonstrate its role in p53 mediated apoptosis pathway. 2020 , 19, 582-595	3
226	Circular RNA profile of acute myeloid leukaemia indicates circular RNA annexin A2 as a potential biomarker and therapeutic target for acute myeloid leukaemia. 2020 , 12, 1683-1699	9
225	[Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors]. 2017 , 38, 1024-1030	0
224	[Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients]. 2017 , 38, 1017-1023	
223	[A single-center, randomized controlled trial of PEG-rhG-CSF and common rhG-CSF to promote neutrophil recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia]. 2019 , 40, 497-501	1
222	[Comparison of 10 mg/m ² or 8 mg/m ² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia]. 2015 , 36, 225-9	2
221	[Outcome of acute myeloid leukemia with FLT3-ITD mutation treated by allogeneic hematopoietic stem cell transplantation]. 2018 , 39, 634-640	

220	[Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms]. 2016 , 37, 221-6	0
219	[Analyses of outcome and prognostic factors of adult acute myeloid leukemia patients received autologous hematopoietic stem cell transplantation]. 2016 , 37, 464-8	
218	[Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia]. 2017 , 38, 185-191	1
217	[Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients]. 2017 , 38, 10-16	1
216	[How I treat acute myeloid leukemia with t (8;21)]. 2017 , 38, 6-9	0
215	[The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts]. 2017 , 38, 876-882	0
214	Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study. 2020 , 10, 124-133	5
213	Analysis of outcomes in hospitalized pregnant patients with acute myeloid leukemia. 2020 , 10, 68-75	1
212	An updated account on molecular heterogeneity of acute leukemia. 2021 , 11, 22-43	1
211	[Spectrum of gene mutations and clinical features in adult acute myeloid leukemia with normal karyotype]. 2021 , 42, 420-424	
210	A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia. 2021 , 11, 325-360	
209	Machine learning finds new AML subtypes. <i>Blood</i> , 2021 , 138, 1790-1792	2.2
208	Molecular associations, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia (Alliance). 2021 ,	1
207	Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. 2021 ,	2
206	Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation. 2021 , 612, 121296	1
205	CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. 2021 ,	0
204	Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy. 2021 ,	0
203	Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. 2021 , 13,	

202	Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: Results from a large multicenter study. 2021 ,		2
201	Corilagin induces apoptosis and inhibits autophagy of HL-60 cells by regulating miR-451/HMGB1 axis. 2022 , 25,		
200	The role of circular RNA plasmacytoma variant translocation 1 as a biomarker for prognostication of acute myeloid leukemia. 2021 , 26, 1018-1024		1
199	Novel Mango Ginger Bioactive (2,4,6-Trihydroxy-3,5-diprenyldihydrochalcone) Inhibits Mitochondrial Metabolism in Combination with Avocatin B.. 2022 , 7, 1682-1693		
198	Prognostic significance of serum ferritin levels on initial diagnosis in patients with acute myeloid leukemia. 2021 , 2, 362-370		
197	Prognostic Significance of Flow Cytometry Findings in Brazilian Patients with De Novo Acute Myeloid Leukemia.		
196	Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.. <i>Blood</i> , 2022 ,	2.2	3
195	High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in Acute Myeloid Leukemia.. 2022 , 14,		1
194	Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy.. 2022 , 28, 14-20		0
193	MicroRNA-199a deficiency relates to higher bone marrow blasts, poor risk stratification and worse prognostication in pediatric acute myeloid leukemia patients.. 2022 , 1-8		1
192	Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival.. 2022 , 14,		1
191	A Proteomic Platform Enables to Test for AML Normalization .. 2022 , 10, 826346		0
190	Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells .. 2022 , 47,		0
189	A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.. 2022 , 1		
188	A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol.. 2022 , 17, e0263195		
187	Decreased expression of autophagy-related genes in the complete remission phase of acute myeloid leukemia.. 2022 , e1872		1
186	Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin. 2022 , 2022, 1-7		
185	Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.. 2022 , 101, 855		0

- 184 Leonurus Japonicus Houttuyn Induces Reactive Oxygen Species-Mediated Apoptosis Via Regulation of Mir-19a-3p/Pten/Pi3k/Akt in U937 and Thp-1 Cells.
- 183 Radionuclide Therapy of Leukemias and Multiple Myeloma. **2022**, 1-52
- 182 Prognostic risk factors for early death in patients with acute myeloid leukemia. **2022**, 3, 16-25
- 181 Adaptation of HL7 FHIR for the exchange of patients' gene expression profiles.
- 180 Role of Biomarkers in FLT3 AML. **2022**, 14, 2
- 179 Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. **2022**, 14, e2022025 0
- 178 Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML. **2022**, 1 1
- 177 Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse. **2022**, 14, 547-559
- 176 DesA Prognostic Risk Model of LncRNAs in Patients With Acute Myeloid Leukaemia Based on TCGA Data. **2022**, 10, 818905 0
- 175 Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy. **2022**, 12, 15 0
- 174 European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. **2021**, 6
- 173 DDX41 is needed for pre- and postnatal hematopoietic stem cell differentiation in mice. **2022**, 2
- 172 Gene Mutations, rs16754 Variant, and Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients. **2022**, 11,
- 171 Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study. **2022**, 12, 804961 1
- 170 Construction of a Pyroptosis-Related Signature for Prognostic Prediction and Characterization of Immune Microenvironment in Acute Myelogenous Leukemia. **2022**, 15, 2913-2927 0
- 169 A phase 1 study of IDH305 in patients with IDH1-mutant acute myeloid leukemia or myelodysplastic syndrome. **2022**, 1 2
- 168 Reverse Electrochemical Sensing of FLT3-ITD Mutations in Acute Myeloid Leukemia Using Gold Sputtered ZnO-Nanorod Configured DNA Biosensors. **2022**, 12,
- 167 Analysis of Argrophilic Nucleolar Organizer Regions (AgNORs) in Acute Leukemia in Adults. **2022**, 12,

166	Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.. 2022,	1
165	Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.. 2022, 58,	1
164	Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies.. 2022, 1	1
163	Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells.. 2022, 11,	0
162	Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.. 2022, 101, 1031	1
161	BAALC gene expression tells a serious patient outcome tale in NPM1-wild type/FLT3-ITD negative cytogenetically normal-acute myeloid leukemia in adults.. 2022, 95, 102662	1
160	FDA Approval Summary: Oral Azacitidine For Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.. 2022,	0
159	Leonurus japonicus Houltuyn induces reactive oxygen species-mediated apoptosis via regulation of miR-19a-3p/PTEN/PI3K/AKT in U937 and THP-1 cells.. 2022, 291, 115129	0
158	Perfil clínico-epidemiológico e sobrevida hospitalar dos casos de leucemia aguda em um hospital de referência em Rio Branco, Acre, 2007-2014. 2021, 29, 351-365	2
157	Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes. 2021, 1-10	0
156	Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy.. 2021,	1
155	Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.. 2021, 13,	2
154	The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.. 2021,	1
153	Advances in Therapeutic -Nucleosides and -Nucleic Acids with Unusual Handedness.. 2021, 13,	0
152	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.. 2022,	1
151	Targeting -Mutated Acute Myeloid Leukemia: Research and Clinical Developments.. 2022, 15, 423-436	3
150	Bone marrow. 813-942	
149	Table_1.DOCX. 2020,	

148 Data_Sheet_1.pdf. **2020**,

147 Image_1.TIF. **2020**,

146 Image_1.JPEG. **2019**,

145 Image_2.TIF. **2019**,

144 Table_1.docx. **2019**,

143 Image_1.TIF. **2020**,

142 Image_2.TIFF. **2020**,

141 Table_1.XLSX. **2020**,

140 Table_2.XLSX. **2020**,

139 Table_1.pdf. **2019**,

138 Data_Sheet_1.ZIP. **2020**,

137 Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive chemotherapy.. **2022**, 1-8

136 Cytogenetic abnormalities in patients with hematological malignancies in Lahore city, Pakistan. **2021**, 83, e249911

135 Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study.. **2021**, 20, 29-32

134 A Phase I trial of talazoparib in patients with advanced hematologic malignancies. **2021**, 10, IJH35

133 Overexpression of Prohibitin 2 Protein is Associated with Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.. **2022**, 42, 585-589

132 [Isolated myeloid sarcoma]. **2021**, 42, 878-880

131 [Analysis of risk factors of relapse after allogeneic hematopoietic stem cell transplantation in patients with t (8;21) acute myeloid leukemia].. **2021**, 42, 998-1004

- 130 Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications.. **2022**, 0
- 129 First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.. **2022**, 1 0
- 128 Blockade of p38 MAPK overcomes AML stem cell line KG1a resistance to 5-Fluorouridine and the impact on miRNA profiling.. **2022**, 17, e0267855 1
- 127 eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia.. **2022**, 9, 877117 0
- 126 Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy. 11, 495
- 125 Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.. **2022**,
- 124 The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia.
- 123 Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial. 0
- 122 Redox Metabolism Maintains the Leukemogenic Capacity and Drug Resistance of AML Cells.
- 121 Patient Perceived Financial Burden in Haematological Malignancies: A Systematic Review. **2022**, 29, 3807-3824 0
- 120 Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature. 12,
- 119 A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan + clofarabine in allogeneic stem cell transplantation.
- 118 Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.
- 117 Long Noncoding RNA Small Nucleolar RNA Host gene 1 is not Only Overexpressed, But Also Correlates with Increased White Blood Cell Count, Deteriorate Induction Treatment Response and Poor Survival Profile in Adult Acute Myeloid Leukemia Patients.
- 116 Integrated pan-cancer analysis reveals distinct clinical, genomic and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia. **2022**,
- 115 One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia. 13,
- 114 Central nervous system involvement in adult acute myeloid leukemia patients. **2022**, 118, 106882
- 113 Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. **2022**, 14, 2817

- 112 The Emerging Roles of Aldehyde Dehydrogenase in Acute Myeloid Leukemia and its Therapeutic Potential. **2022**, 22,
- 111 Daunorubicin-60 vs daunorubicin-90 vs idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.
- 110 Novel mitochondria-targeting compounds selectively kill human leukemia cells.
- 109 Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study. **2022**, 11, 916 2
- 108 Preoperative Evaluation and Preparation for Ovarian Tissue Transplant Surgery. **2022**, 109-115
- 107 A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. 28, 1
- 106 Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification. **2022**, 14, 3199 1
- 105 Effects of immune response and time delays in models of acute myeloid leukemia.
- 104 Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. **2022**, 14, 3456 3
- 103 Ectopic viral integration Site-1 oncogene promotes NRAS pathway through epigenetic silencing of microRNA-124 in acute myeloid leukemia. **2022**, 110402
- 102 Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web-based case vignette questionnaire: The MINDSET study.
- 101 Croton caudatus Geiseler Induces Differentiation of the Acute Myeloid Leukemia cell lines.
- 100 Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. **2022**, 17, e0270744
- 99 Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. *Blood*, 2.2 60
- 98 Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy. 11, 495
- 97 Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience. 0
- 96 Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience. **2022**, 10, 0
- 95 Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from *Brucea antidysentrica* for acute myeloid leukemia. **2022**, 17, e0270050 3

- 94 The mythological chimera and new era of relapse prediction post-transplant. **2022**, 100997 ○
- 93 Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
- 92 Identification of GTF2IRD1 as a novel transcription factor essential for acute myeloid leukemia.
- 91 Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern. 1
- 90 Construction of a solid Cox model for AML patients based on multiomics bioinformatic analysis. 12, ○
- 89 Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia. 10, 1
- 88 Vulvovaginal myeloid sarcoma with massive pelvic floor infiltration: A case report and review of literature. **2022**, 10, 8312-8322
- 87 Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis. 12, ○
- 86 Thiotepa-fludarabine-breosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial. ○
- 85 No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group. **2022**, 2022, 1-9
- 84 Lesions learned from therapy-related acute myeloid leukemia.
- 83 Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. 1
- 82 MicroRNA-181b-5p insufficiency predicts treatment response failure risk and unfavorable event-free survival as well as overall survival in acute myeloid leukemia patients. **2022**, 24,
- 81 Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients. **2022**, 12, 2
- 80 Research Progress of Long Non-Coding RNA Regulating Glucose Metabolism in Acute My-eloid Leukemia Cells. **2022**, 12, 7865-7870 ○
- 79 Radionuclide Therapy of Leukemias and Multiple Myeloma. **2022**, 1329-1380 ○
- 78 Research Progress of CircRNAs in Acute My-eloid Leukemia. **2022**, 12, 7871-7876 ○
- 77 Genetic and immunophenotypic diversity of acute leukemias in children. **2022**, 76, 369-379 ○

76	Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.	0
75	A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. 2022 , 14, 4166	0
74	Case report: A <i>Saprochaete clavata</i> (<i>Magnusiomyces clavatus</i>) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma. 12,	0
73	Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulphan Conditioning: A Retrospective Monocentric Study. 2022 ,	1
72	Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. 2022 , 15,	0
71	Overview of Molecular Quantification of the BCR-ABL Oncogene in CML Patients. 2022 , 19, 693-698	0
70	Prognostic characteristics of immune subtypes associated with acute myeloid leukemia and their identification in cell subsets based on single-cell sequencing analysis. 10,	0
69	Comprehensive analysis of ECHDC3 as a potential biomarker and therapeutic target for acute myeloid leukemia: Bioinformatic analysis and experimental verification. 12,	0
68	High-dimensional genomic feature selection with the ordered stereotype logit model.	0
67	CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. 2022 , 12,	2
66	Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia. 2022 , 13, 204062072211323	0
65	A glimpse into translocation (8;21) in acute myeloid leukemia: Profile and therapeutic outcomes from a tertiary care hematology center from East India. 2, 85-90	0
64	Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.	0
63	Blood MALT1 deficiency is common and relates to unfavorable induction therapy response and survival profile in acute myeloid leukemia patients. 2022 , 27, 1176-1183	0
62	In Vitro and In Vivo Characterization of 89Zirconium-Labeled Lintuzumab Molecule. 2022 , 27, 6589	0
61	Successful Treatment of Isolated Central Nervous System Relapse with Intrathecal Chemotherapy in an Adolescent with Acute Promyelocytic Leukemia. 2022 , 29, 70-73	0
60	Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia. 2022 , 13,	0
59	Naturally Selected CD7 CAR-T Therapy without Genetic editing Exerts Significant Antitumor Efficacy against Relapsed and Refractory Acute Myeloid Leukemia(R/R-AML).	0

58	Immunotherapy approaches for hematological cancers. 2022 , 25, 105326	0
57	Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia.	0
56	The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia.	0
55	De novo pancytopenia in an older adult with severe COVID-19 infection. 2022 , 15, e252609	0
54	Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.	0
53	Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. 2022 , 12,	2
52	Leucemie mieloidi acute. 2022 , 24, 1-11	0
51	Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. 2022 , 12,	0
50	Allogeneic stem cell transplant improves survival after first- or second-line therapy in TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)..	0
49	A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia. 13,	0
48	Clinical response to upfront targeted tyrosine kinase inhibitors among patients with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusion.. 2022 ,	0
47	High expression of B4GALT1 is associated with poor prognosis in acute myeloid leukemia. 13,	0
46	Central Nervous System Prophylaxis and Treatment in Acute Leukemias. 2022 , 23, 1829-1844	0
45	Optimization of tyrosine kinase inhibitor-loaded gold nanoparticles for stimuli-triggered antileukemic drug release.	0
44	Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.	0
43	Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML. 12,	0
42	Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia. 2022 , 22,	0
41	Early-onset venous thromboembolisms in newly diagnosed non-promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy.	0

- 40 Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML). **2022**, 20, ○
- 39 Genetic changes in refractory relapsed acute myeloid leukemia with NPM1 mutation: A case report. 10, 13058-13063 ○
- 38 Bioactive Compounds from Curcuma amada and their effect on Acute Myeloid Leukemia. **2023**, ○
- 37 Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes. ○
- 36 N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. **2023**, 98, 290-299 ○
- 35 Circular RNA SPI1 expression before and after induction therapy and its correlation with clinical features, treatment response, and survival of acute myeloid leukemia patients. ○
- 34 SETD2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients. **2023**, 28, ○
- 33 Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia. **2023**, 126, 107019 1
- 32 Association of Platelet Count Detected by Novel Nano Probe with Prognosis After Initial Chemotherapy in Patients with Acute Myeloid Leukemia. **2022**, 18, 2433-2438 ○
- 31 Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review. **2022**, ○
- 30 Incidence and risk factors for development of cardiac toxicity in adult patients with newly diagnosed acute myeloid leukemia. ○
- 29 Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. **2023**, ○
- 28 Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. ○
- 27 Genetic Mutation Signature for Relapse Prediction in Normal Karyotype Acute Myeloid Leukemia. ○
- 26 2-Aminopyrimidine derivatives as selective dual inhibitors of JAK2 and FLT3 for the treatment of acute myeloid leukemia. **2023**, 134, 106442 ○
- 25 SLED1 Promoting Cell Proliferation and Inhibiting Apoptosis in Acute Myeloid Leukemia: a Study. ○
- 24 Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia. **2023**, 24, ○
- 23 Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse. 13, ○

22	Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis. 2023 , 102, 761-768	○
21	Investigation of distinct gene expression profile patterns that can improve the classification of intermediate-risk prognosis in AML patients. 14,	○
20	Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). 2023 , 37, 799-806	○
19	Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation. 2023 , 15, 1312	○
18	Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. 2023 , 37, 788-798	○
17	Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse?. 2023 , 15, 1425	○
16	Analysis of the differential expression and prognostic relationship of DEGs in AML based on TCGA database. 2023 , 28,	○
15	Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.	○
14	Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. 2023 , 98, 760-769	1
13	Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. 2023 , 91, 281-290	○
12	Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study. 2023 , 15, 1609	○
11	CPT1B, a metabolic molecule, is also an independent risk factor in CN-AML. 2023 , 1-13	○
10	The expression level of Neuronal Calcium Sensor 1 can predict the prognosis of cytogenetically normal AML.	○
9	Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience. 2023 , 102, 1045-1052	○
8	The expression level of ARF and p53 in AML patients, and their relation to patients' outcome. 2023 , 24,	○
7	Updates in molecular genetics of therapy-related myeloid neoplasms. 2023 ,	○
6	Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.	○
5	Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia. 2023 , 15, 2267	○

- 4 Identification and validation of a novel CD8+ T cell-associated prognostic model based on ferroptosis in acute myeloid leukemia. 14,
- 3 Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia. 1-7
- 2 A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. 14,
- 1 Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing. 2023,